Living evidence synthesis · Psilocybin
Does one dose of psilocybin rewire the brain?
Does a single dose of psilocybin rewire the brain, and for how long?
Ask twenty-four sources whether one dose of psilocybin rewires the brain and you get different answers. They differ in who was dosed, what was measured and which species, and in dose, setting and timing too. Whether any of these explains the disagreement is a question we pose here, not a finding.
About our editorial responsibility · How to read the research
Evidence intelligence, not medical advice. Nothing here recommends using psilocybin or any controlled substance.
What we mean by rewire. Four different things get called rewiring, and this record keeps them apart: structural change, such as new spines or synapses; functional connectivity, how regions' activity moves together; molecular markers tied to plasticity; and symptom change. Evidence for one is not evidence for another.
What changed
Since the last published record
Measured from the record published on 9 November 2026. Newest first, each with its own date.
15 newly linked works found on 9 November 2026.
Trust panel
How much to trust this
Counts computed, judgments editorial
What we read against what the citation graph says we should, how many separate research programs the evidence rests on, how far we would stake each claim, what would change our mind, and when this was last checked. Counts are computed from this synthesis and its latest scan. Which studies to include, the tier of each claim and how studies relate are editorial judgments. Reasons for claim tiers and relations appear below. Screening reasons await signing.
Coverage
24 sources. 7 read in full.
None yet checked by two AI models and signed.0
24 of 145 works in the coverage set are sources.
103 works included after screening, of 294 citation-linked. 8 measured the brain after the acute effects, 18 during the drug, and 12 at a time not yet sorted. 40 report patient outcomes without a qualifying post-dose brain measure, 3 test mechanism, and 22 are indirect evidence:
- 6 animal behaviour-only studies testing persistence, replication, dose, context or receptor dependence, including null results
- 2 controlled studies of lasting psychological or behavioural outcomes in healthy volunteers
- 3 receptor-blocking or receptor-manipulation studies
- 10 plasticity studies of other serotonergic psychedelics
- 0 studies of how a brain measure should be read under psychedelics
- 1 qualifying results after more than three doses
Inclusion means relevance, not support for lasting brain change.
99 records listed as context, including reviews, commentaries and protocols. 74 excluded as out of scope. 18 still pending.
Screening has decided 276 of 294 retrieved works. See the full screening list. How the screening counts relate, scan by scan.
Candidates to read, most connected first:
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016, 2,318 citations) · Direct
- Psychedelics Promote Structural and Functional Neural Plasticity (2018, 1,296 citations) · Direct
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder (2022, 767 citations) · Direct
- Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels (2019, 547 citations) · Direct
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder (2020, 1,397 citations) · Direct
And 116 more candidates to read.
How this was computed
Sources and read in full come from this synthesis's read-depth audit. A source counts as read in full only with a dated record that the complete paper was read. The split of included works comes from the rule and the timing flag on each screening decision.
The coverage set behind the tick is the seed papers this synthesis reads, plus every citation-linked work in the recorded OpenAlex scan that has not been screened out. A work decided context or excluded leaves the set at once. For scale, OpenAlex indexes 16,950 works for “psilocybin”.
Gaps are ordered by how many of this record's sources they connect to, then by citations. A gap is a candidate to read.
Independence
15 author programs
across 24 sources
Lyons 2026 and Daws 2022 and Carhart-Harris 2021 and Pasquini 2026 and Harding 2025 and Erritzoe 2024 share 14 authors (Adam H. Gazzaley, Ashleigh Murphy-Beiner, Bruna Giribaldi, …).
Jiang 2026 and Shao 2021 share 4 authors (Alex C. Kwan, Ling-Xiao Shao, Neil K. Savalia, …).
Goodwin 2022 and Raison 2023 share 2 authors (Boadie Waid Dunlop, Tanja Mletzko).
Johansen 2026 and Madsen 2024 and Brendstrup-Brix 2026 share 11 authors (Anja Sofie Petersen, Annette Johansen, Brice Ozenne, …).
Tied, not merged: Robin Lester Carhart-Harris is a co-author across otherwise separate programs (Lyons 2026 + Daws 2022 + Carhart-Harris 2021 + Pasquini 2026 + Harding 2025 + Erritzoe 2024; Goodwin 2022 + Raison 2023; Siegel 2024).
Tied, not merged: Charles L. Raison is a co-author across otherwise separate programs (Goodwin 2022 + Raison 2023; Siegel 2024).
Tied, not merged: Patrick M. Fisher is a co-author across otherwise separate programs (Johansen 2026 + Madsen 2024 + Brendstrup-Brix 2026; Gudmundsen 2026).
Claim 11, 16 draws on more than one source but only one program.
Relation 2 → 1 (population difference); 9 → 2 (measures differently); 4 → 10 (extends); 14 → 1 (measures differently); 17 → 2 (measures differently); 2 → 1 (population difference, posed) compares studies from the same program.
How this was computed
Two sources belong to the same research program when they share at least two authors, or the same lead or senior author (first or last listed), matched on surname and first initial. Programs are the connected groups in that graph. A single shared mid-list co-author, common on large trials, is shown as a tie between programs rather than merged. Author lists come from the corpus snapshot (full lists).
Shared authors are a reason to check for common methods, datasets and participants. Authorship alone does not establish whether findings are dependent or independently replicated.
This counts authorship groups, not independent cohorts. A group can contain separately recruited participants, and separate groups can still share participants, data or a sponsor. Those ties are named in the claims below and are not yet part of this count.
Evidence tiers
23 claims, 13 relations
Claims
1Established22PreliminaryRelations
3Active debate9Preliminary1Our interpretationRelation 2 → 1 (population difference, posed) is our own reading, posed as a question: 2 automated stress tests. Checked by AI against the recorded claims of all 24 studies here, not their full texts. Expert review: invited. Offer to review it.
How this was computed
Every claim and relation carries a tier and the reason for it, printed beside it below. Tiers never rely on colour alone.
A novel reading (our interpretation, or anything posed as a question) ships only after at least two automated stress tests with separate briefs failed to refute it. It stays labelled as a question until a named expert reviews it. Ungated novel items: 0.
Living status
Version 2.2
Conclusion last changed 24 October 2026
Corpus scanned 9 November 2026
121 candidates to read. 68 new works entered the scan since 4 November 2026.
Revised 11 times; last updated 9 November 2026.
How this was computed
A major version means a conclusion moved. A minor version means the synthesis reads more of the field. Wording changes do not bump the version. The scan runs weekly and opens a reviewable pull request; this tile shows the latest reviewed scan.
Revision history is in the living log. Scan history is in Scan by scan.
Screening
Scan by scan
7 citation scans, newest first
| Scan | Found | Citation-linked | Screened | Included | Context | Excluded | Pending | Candidates to read | Scoping verdicts |
|---|---|---|---|---|---|---|---|---|---|
| 9 November 2026 | 1,670 | 294 | 276 | 103 | 99 | 74 | 18 | 121 | 150 |
| 4 November 2026 | 1,626 | 280 | 277 | 103 | 99 | 75 | 3 | 106 | 153 |
| 26 October 2026 | 1,595 | 277 | 0 | 0 | 0 | 0 | 277 | 277 | 154 |
| 19 October 2026 | 1,593 | 276 | 0 | 0 | 0 | 0 | 276 | 276 | 153 |
| 14 October 2026 | 1,589 | 275 | 0 | 0 | 0 | 0 | 275 | 275 | 155 |
| 12 October 2026 | 1,588 | 276 | 0 | 0 | 0 | 0 | 276 | 276 | 155 |
| 28 September 2026 | 521 | 34 | 0 | 0 | 0 | 0 | 34 | 30 | 161 |
Found: every candidate the scan reached from the seed papers. Citation-linked: those linked to two or more seeds, which this synthesis must screen. Screened counts decisions on those works under this synthesis's own rules: included, context or excluded. Context means a review, commentary or protocol listed but not counted; excluded means out of scope. Pending means no decision yet, so citation-linked is screened plus pending. Each row includes decisions saved with its scan and screening later filed against that scan. The newest row also includes current decisions carried forward from earlier scans. Candidates to read: citation-linked works this synthesis does not cite and has not screened out, as the trust panel lists them. Scans overlap, so counts do not add across rows. Scoping verdicts: candidates that carry a verdict from the scoping pass of 10 October 2026, pending ones included. That pass asked a narrower question under rules of its own, so its verdicts do not count as screened here. It screened 335 records: 161 candidates from the scan of 28 September 2026 and 174 from keyword searches. Of those, 20 were included, 300 excluded and 15 left pending a full-text check. See the full screening list.
How this was computed
Counted when the site is built, from every saved scan of this synthesis and its latest screening record. A decision counts only when it was made under this synthesis's current rules; if the rules change, older decisions stop counting until someone looks at them again.
Fragility
What would change our mind
- Claim 1
A pre-registered, adequately powered study in healthy volunteers finds enduring functional brain change at one month or later. That would move this from preliminary to active debate; an independent replication of the null would move it toward established.
- Claim 2
An independent research program fails to find increased global integration in depression patients, or finds it without any link to antidepressant response. A second independent replication would move this toward established.
- Claim 4
An independent lab fails to find the network-specific input reorganization with rabies tracing, or finds that it survives silencing of the presynaptic region during dosing. Either would move the mechanism from preliminary to active debate.
- Claim 13
A larger or independently replicated PET study finding a significant overall increase in synaptic density after one dose would move the human question to active debate. A preregistered test of the setting effect would show whether the subgroup difference holds.
How this was computed
Authored lines, quoted verbatim, for the claims the argument rests on. A tier without a stated condition for revising it is an opinion. A computed fragility index follows once appraisal fields exist on every claim.
What the evidence says
The headlines can't agree. Some say a single dose rewires the brain and opens a weeks-long window of change; others, that the brain quietly returns to normal within a month. Both are describing real studies. Part of the disagreement comes from the science being fragmented: different labs, populations, and instruments, rarely read side by side.
Put side by side, the two best-known results come from different people. In depression patients given two doses with therapy support, psilocybin increased the brain's overall “integration,” and bigger changes went with bigger improvements in mood (Daws, 2022). In healthy volunteers given one dose, a newer study found that a month later the enduring changes in how the brain functions were “largely absent”: what lasted was mainly how people felt (Lyons, 2026). Same drug, opposite-sounding results, and one studied depressed people, the other healthy ones, with different doses, support and timing too.
The healthy side isn't a clean zero, though. A study that scanned seven healthy adults over and over (before, during and for weeks after a dose) found the brain's networks thrown far out of sync during the experience, with most of that fading afterwards. An exploratory analysis in six of them suggested one link, between the hippocampus and the brain's “default-mode” network, stayed weaker during three weeks of follow-up (Siegel, 2024). In the healthy-volunteer studies here, lasting change looks narrower than in patients, but not absent; they measured at different times, and earlier studies, from before this update's search window, are not included.
And treatment is a separate question from rewiring. In 233 people with hard-to-treat depression, one 25 mg dose beat a tiny control dose at three weeks, but a lasting benefit beyond that was not established (Goodwin, 2022). In a head-to-head trial against a standard antidepressant, psilocybin did not clearly win on the main measure after six weeks (Carhart-Harris, 2021). In another trial, of 104 people with depression, one dose lowered depression scores more than an active placebo six weeks later (Raison, 2023, read from the abstract). Six months after the head-to-head trial, both groups were still better, but by then patients could seek other treatment and some data were missing, so that follow-up cannot show how long the drug's own effect lasts (Erritzoe, 2024). The brain scans in depression patients here stop at about three weeks after the second dose; symptoms have been followed for longer, and the two horizons are different questions.
The measure matters too. In mice, one lab found that one dose visibly remodels the wiring: new connections sprout in the frontal cortex within a day and, in a subset of mice imaged again, are still there a month later (Shao, 2021). The same lab later found that one dose also reorganizes which brain regions send input to neurons in that part of the frontal cortex, and that silencing one input region during dosing interfered with that change (Jiang, 2026). Structural and functional measures can tell different stories, in both directions: in rats, a later study found neuron function changed months after one dose with no structural difference detected (Kramer, 2026, below). So “rewiring” and “function returned to baseline” need not contradict each other, but which pattern holds, and in which species, is open. The most direct human test so far found no significant rise: in 15 healthy adults, synaptic density measured by PET one week after a dose did not rise significantly overall, though in a small exploratory comparison, people dosed in a therapy-like room showed more of an increase in the frontal cortex than people dosed in a scanner, though the room group's own change was not significant (Johansen, 2026).
And the famous “four-week window”? That comes from a mouse study showing psychedelics reopen a critical period for social learning, with the window scaled to how long the trip lasts: about two weeks for psilocybin, four for ibogaine (Nardou & Dölen, 2023). It's a striking result, but it's about a specific kind of learning in mice, not a proven four-week rewiring of the human brain. The popular version seems to borrow ibogaine's number and stretch a mouse finding onto people.
Newer sources, added in version 2.2, include studies and reviews of brain measures a week or more after dosing. They add detail more than a verdict. In people, the findings at one to four weeks are few and mixed. A re-analysis of the Lyons volunteers found activity in one set of brain circuits more variable over time four weeks after the high dose than four weeks after the tiny control dose, but only a trend against where people started, evidence the authors call weak to moderate (Pasquini, 2026). In ten people given three low-to-moderate doses in random order, one connectivity change rose with dose and survived correction a week after a dose, and many network changes tracked how strongly the dose altered consciousness (Bhagavan, 2026, a preprint read from the abstract). In a small cluster headache trial with three doses, a change in hypothalamic connectivity tracked how much attacks fell (Madsen, 2024), and a later analysis of the same trial detected no statistically significant change in brain microstructure a week after the last dose, in the 8 of 11 patients scanned again (Brendstrup-Brix, 2026). Depression patients from the escitalopram trial showed changed brain responses to surprises in music three weeks after their second session, though how they felt about the surprises did not change significantly (Harding, 2025). One 2026 review found follow-up scans missing from most psilocybin brain-imaging studies published to mid-2024, and another, in depression, warned that many studies reuse the same datasets.
The longest-lasting brain change after a single dose in this set is in rats given psilocybin or a similar drug: several months later, prefrontal neurons still behaved differently after either drug, while no difference in synaptic density or spine types from control rats was detected, a result the abstract does not split by drug (Kramer, 2026, read from the abstract). Other animal studies detected few brain changes or none at one week to one month (Gudmundsen, 2026; Keenan, 2026), and two studies that dosed young rodents repeatedly found brain differences weeks to months later whose meaning is unclear (Sahoo, 2026; García-Cabrerizo, 2025).
One more thing worth knowing: six of the human papers here come from the same research program and draw on just three groups of participants; two more share a single co-author with it, a link rather than the same team; three more come from one Copenhagen team, two of them from the same cluster headache trial; the two single-dose depression trials share two authors; and both mouse rewiring studies come from one lab. Papers that reuse the same participants aren't independent confirmations, and shared authors alone don't mean shared data. A large new study following 62 people out to a year (PsiConnect) may help settle it, but it's still a preprint.
Our reading, offered as a question, not a verdict: could the “does it rewire the brain?” fight partly dissolve once you separate patients from healthy people, structure from function, and rodents from humans? We pose it; the twenty-four sources here don't test it, and the last two lines overlap, because synapses have been measured almost only in rodents. Their findings are mixed and mostly exploratory, they differ in dose, support, timing and measure as well as in who was studied, and a result that reaches significance in one group but not another doesn't show the groups differ. Clear lasting structural change after one dose comes from one mouse lab. A study of obese mice detected no difference in synaptic proteins a month later, the one human synaptic-density study detected no significant rise a week later, and the Lyons volunteers kept some changes on diffusion scans a month later. A rat study found neurons still working differently months after one dose of psilocybin or a similar drug, with no difference in synaptic density detected, though its abstract does not say whether that held for psilocybin on its own. The open question is whether the broad change seen in patients is specific to the depressed brain rather than a general effect of the drug. It's also possible the brain change follows the mood improvement rather than drives it, that what people expected explains part of it, and that reused samples make the pattern look firmer than it is. Every human brain-imaging sample here is small, several newer studies were read only from abstracts, and in the patient brain-imaging studies included here the scans stop at about three weeks, so how long any brain or symptom effect of the drug lasts is not settled. That's a question for the next round of research, not a claim we can bank today.
Twenty-four sources, one apparent contradiction. We pose population, measure and species as possible explanations, untested here; dose, setting, timing and analysis differ too, and several human papers reuse the same samples.
Human, patients (Daws 2022, Nat Med). Two depression trials, two doses each with psychological support; psilocybin decreased fMRI network modularity (increased global integration), and integration change correlated with antidepressant response. Imaging to ~3 weeks after the second dose; how long the brain change lasts was not measured. Subscription article: cited, not reproduced.
Human, healthy (Lyons 2026, Nat Commun). Within-subjects, 28 enrolled, 25 vs 1 mg. Acute EEG changes (LZc↑, alpha↓, p<0.001); at one month, enduring functional changes “largely absent,” with some persistent DTI/modularity signals; psychological gains endured (well-being d = 0.6, insight d = 1.2). Exploratory, not pre-registered.
Mouse, mechanism (Jiang 2026, Cell). Monosynaptic rabies tracing of the inputs to frontal cortex pyramidal neurons: one dose reorganizes them in a network-specific way (strengthens DMN-homolog→subcortical routing, weakens cortico-cortical recurrence); silencing a presynaptic region during dosing interfered with the rewiring, so it depends on drug-evoked spiking. The result concerns traced inputs, not dendritic spines. CC-BY-NC (cited).
Mouse, critical period (Nardou/Dölen 2023, Nature). Psychedelics reopen the social-reward-learning critical period; window duration ∝ acute subjective duration (psilocybin ~2 wk; ibogaine ~4 wk); mechanism via oxytocin-mediated LTD and ECM remodeling. CC-BY.
Human, preprint (PsiConnect 2025, bioRxiv). Multi-echo fMRI + structural/DWI + EEG, n = 62, 19 mg, resting + naturalistic paradigms, follow-up to one year. Not peer-reviewed; CC-BY-NC-ND.
Human, healthy, precision mapping (Siegel 2024, Nature). n = 7, dense repeated fMRI before, during and after 25 mg, methylphenidate as active control. Acute functional-connectivity desynchronization far larger than control; most changes normalized within days; an exploratory persistence analysis (n = 6, 186 observations pooled over days 1 to 21, uncorrected P = 0.0033 after a regional screen) suggested decreased anterior hippocampus–default-mode connectivity during the three weeks scanned; values appeared near baseline at a 6 to 12 month revisit (n = 4, underpowered). CC BY 4.0 (cited).
Human, TRD trial (Goodwin 2022, NEJM). Phase 2b, n = 233, single dose 25 / 10 / 1 mg with psychological support; MADRS change at week 3 favored 25 mg over 1 mg, 10 mg did not separate; durability beyond week 3 not established. Adverse events including suicidal ideation or self-injury in all groups. Sponsor: COMPASS Pathways.
Human, active-comparator trial (Carhart-Harris 2021, NEJM). Phase 2, n = 59, two 25 mg doses vs daily escitalopram (plus 1 mg psilocybin) over six weeks; primary QIDS-SR-16 difference not significant; secondaries favored psilocybin without multiplicity correction. Part of Daws's imaging comes from this trial.
Mouse, spines (Shao 2021, Neuron). Chronic two-photon imaging in medial frontal cortex; one dose increased spine density and size within 24 hours, still above baseline a month later. Kwan lab, as Jiang 2026. License not yet checked (cited).
Human, healthy, synaptic density (Johansen 2026, Transl Psychiatry). 0.3 mg/kg, [11C]UCB-J PET (SV2A) in frontal cortex and hippocampus at baseline and one week; open-label, single arm, no placebo. No significant overall increase: VT at an interim analysis of the 12 with complete arterial data, mean change frontal cortex 0.3 mL/cm3 (SD 2.6) and hippocampus 0.3 mL/cm3 (SD 2.0), stopped for futility; BPND in all 15, mean change −0.01 (SD 0.35) frontal and 0.01 (SD 0.28) hippocampal. Exploratory setting contrast in the change in VT, therapy-like room against MRI scanner: frontal cortex 3.0 mL/cm3 (95% CI 0.4 to 5.5), hippocampus 1.9 mL/cm3 (95% CI −0.3 to 3.9). The room group alone: frontal cortex 1.1 mL/cm3 (95% CI −0.5 to 2.7), hippocampus 0.8 mL/cm3 (95% CI −0.5 to 2.1). Accelerated article preview as of 2026-10-05. CC BY 4.0 (cited).
Human, healthy, re-analysis (Pasquini 2026, Hum Brain Mapp). Secondary analysis of the Lyons sample (n = 25, fixed order 1 mg then 25 mg, no placebo). Fronto-striatal-thalamic dynamic functional homogeneity lower 4 weeks after 25 mg than after 1 mg (t(24) = 2.87, p = 0.008), trend against baseline (p = 0.06); order effects at the whole-brain level; modelled structure-function coupling lower after 25 mg, but its group permutation test only a trend (one-sided p = 0.064); effective-connectivity changes rest on repeated simulations, not subject-level tests. Authors call the evidence weak to moderate. CC BY-NC (cited).
Human, healthy, low doses (Bhagavan 2026, medRxiv). n = 10, three doses of 5 to 20 mg in randomized blinded order; resting fMRI at baseline and one week after a dose (which dose in the sequence, and carry-over, not checked). Of 77 nominal dose-dependent edge changes none survived correction; one dose-dependent within-network increase (of 7) survived. Dose-adjusted conscious-state change was positively associated with widespread connectivity change, with many network-level associations surviving correction. Preprint, abstract only.
Human, cluster headache (Madsen 2024, Headache; Brendstrup-Brix 2026, J Psychopharmacol). Open label, three doses of 0.14 mg/kg a week apart, imaging one week after the last. Madsen (10 in the trial; correlation denominator not checked): hypothalamic-diencephalic connectivity change correlated negatively with percent change in attack frequency (R = -0.81, pFWER = 0.03). Brendstrup-Brix, a post hoc analysis of the same EPOCH trial: 11 at baseline, 8 with complete follow-up dMRI; all six Holm-adjusted microstructure comparisons p = 1.00 (nondetection). Madsen abstract only; Brendstrup-Brix full text checked in review. Copenhagen program, as Johansen.
Human, patients, task fMRI (Harding 2025, Mol Psychiatry). Escitalopram-trial patients with usable fMRI (22 psilocybin, 19 escitalopram), scanned three weeks after the second psilocybin session. Greater pre/post decrease after psilocybin than escitalopram in surprise-related vmPFC (ROI interaction F(1,39) = 7.074, p = 0.0113; within-group p = 0.0395, no correction across three ROIs described) and right angular gyrus (whole-brain interaction) responses; sensory-region activity rose within the psilocybin group only, with no region where psilocybin exceeded escitalopram. Same trial and program as Carhart-Harris 2021. CC BY 4.0 (cited).
Systematic reviews (Farré-Colomés 2026, Discov Ment Health; Sabbah 2026, J Affect Disord). Farré-Colomés: follow-up scans lacking in most psilocybin fMRI studies; lasting effects reported up to 4 weeks. Sabbah (depression): some changes grouped as “5+ weeks” (the abstract does not say whether scan or outcome time); many studies reuse overlapping datasets. Sabbah abstract only.
Rat, months (Kramer 2026, Neuropsychopharmacology). One dose; forced-swim effect for at least three months; slice electrophysiology of mPFC layer 5 neurons changed several months later; no difference detected in synaptic density, spine classification or synaptic-marker expression. No overt behavioral differences between psilocybin and 25CN-NBOH, and functional plasticity with both; the abstract does not say whether the structural and expression nulls were tested for each drug. Abstract only.
Rat, one week (Gudmundsen 2026, Nat Commun). n = 12, 1 mg/kg s.c., [18F]FDG-PET normalized to whole-brain mean. Each drug group against its own baseline. One week: insula uptake up (adjusted p < 0.05), mPFC-insula covariance across rats up (adjusted p = 0.04); no psilocybin-only voxel clusters survived FDR; the abstract's one-week hypometabolism pools three drugs. CC BY-NC-ND (cited).
Mouse, 30 days (Keenan 2026, Transl Psychiatry). Diet-induced obese male mice, 1 mg/kg i.p. once, then high-fat diet or chow; no significant treatment difference detected in PSD-95 and synapsin-1 puncta in mPFC (PrL/IL) and hypothalamus at 30 days (n = 5 to 6 per group). CC BY-NC-ND (cited).
Rodent, repeated adolescent dosing (Sahoo 2026, Neuropsychopharmacology; García-Cabrerizo 2025, Biomed Pharmacother). Mice dosed five times (about 3.0 mg/kg by gavage) on postnatal days 40 to 50, MRI at PND 85 (structure, diffusion), 107 (resting) and 176 (odour BOLD): exploratory differences in normalized regional volumes, diffusion measures and connectivity (resting-state n = 10 vs 11, sexes pooled); no area-level sex-by-treatment interaction survived FDR; funder Ekam Imaging, in which two authors hold an interest. Rats dosed daily for 7 days: NeuroD1 (a progenitor-cell marker) higher at day 16 after 1 mg/kg (p = .002), not 0.3 mg/kg (p = .123); associated with day-15 forced-swim escape (r = .418, n = 39, sexes pooled). Methods and Fig. 5 checked in review; complete methods not.
Human, single-dose MDD trial (Raison 2023, JAMA). Phase 2, n = 104, 25 mg against niacin 100 mg, both with psychological support, after medication taper; central-rater MADRS change to day 43, mean difference −12.3 (95% CI −17.5 to −7.2), day 8 −12.0 (95% CI −16.6 to −7.4); sustained response but not remission more frequent; more overall and severe AEs, no serious treatment-emergent AEs. Follow-up ends at day 43. Abstract only; sponsor not checked.
Human, six-month follow-up (Erritzoe 2024, eClinicalMedicine). Observational follow-up of the escitalopram trial: 25 of 30 psilocybin and 21 of 29 escitalopram patients completed; both arms improved, QIDS-SR-16 difference 1.51 (95% CI −1.35 to 4.38; p = 0.311); functioning, connectedness and meaning in life favoured psilocybin. No restrictions on psychiatric care during follow-up; limited power, missing data, self-report; the authors call the results descriptive. Imperial program. CC BY-NC (cited).
Integrity note. Lyons, Daws and Carhart-Harris 2021 share a lead or senior author (Carhart-Harris) and several co-authors, Daws reuses that trial's patients, Pasquini and Harding re-analyse the Lyons sample and the escitalopram trial, and Erritzoe follows up that trial's patients: the six Imperial papers draw on three cohorts. Siegel and Goodwin each list Carhart-Harris as one mid-list co-author, so the trust panel shows each as tied to the Imperial program, not merged with it. Siegel also lists Raison mid-list, so it is tied to the Goodwin and Raison program too, and Gudmundsen is tied to the Copenhagen program through one mid-list co-author (Fisher). Johansen, Madsen and Brendstrup-Brix are one Copenhagen program, and Madsen and Brendstrup-Brix report the same EPOCH trial. Goodwin and Raison share two authors (Dunlop, Mletzko), so the trust panel counts the two single-dose depression trials as one program. Shao and Jiang are one lab.
Posed synthesis (our interpretation, untested; automated checks only, expert review pending). A question, not a finding: could population (patients vs healthy), measure (structure vs function) and species explain the divergence across the twenty-four v2.2 sources? The sources are heterogeneous and mostly exploratory and do not establish whether persistent human network changes are depression-specific. Measure and species overlap: synapse-level structure has been measured almost only in rodents. Prompts: global integration in depression patients after two doses, imaged ≤ 3 weeks (Daws); narrower or weaker persistent change in the healthy-volunteer studies here (Siegel, exploratory, n = 6, uncorrected, near baseline at a 6 to 12 month revisit of four; Pasquini, significant vs 1 mg, trend vs baseline; Lyons, “largely absent” apart from some DTI and modularity signals); clear persistent structural change after one dose from one mouse lab, against structural nondetections in Kramer (rats, months, psilocybin or 25CN-NBOH, not split by drug), Keenan (obese mice, 30 days), Johansen (SV2A, one week) and Brendstrup-Brix (diffusion, cluster headache, one week). Structure and function dissociate in both directions. Testable questions: is the broad human signal depression-specific, and does it hold outside the one program behind six papers on three cohorts, including both sides of the population contrast (Daws, Lyons)? Alternatives and limits: population entangled with dose count, support, age, timepoint, assay and analysis; significant-vs-non-significant is not a population difference; expectancy poorly controlled (only Siegel used a psychoactive control); small human samples, several pre-post designs without placebo; integration may follow mood; abstract-only sources; pre-2024 studies not searched; in the depression-patient imaging studies included here, imaging stops at ~3 weeks, while symptoms improved more than on placebo at day 43 in one trial here (Raison), and at six months both arms of the escitalopram trial were still improved, with no significant difference, in an observational follow-up (Erritzoe), so how long a brain or symptom effect caused by psilocybin lasts is not settled.
One month after a single 25 mg dose vs 1 mg · healthy volunteers · 28 enrolled · exploratory, not preregistered
Mean difference with its 95% confidence interval. Each outcome has its own scale. Right of zero favours 25 mg.
Personal insight
Psychological Insight Scale (PIS), 0 to 100 visual analogue scale
27.86points higher
95% CI 18.90 to 36.82
d = 1.2p < 0.0001Bonferroni-correctedIn the paper: Results, 'Psychological outcomes: psychological insight'; Fig. 4BWell-being
Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS), 14 to 70, 14 items scored 1 to 5
4.70points greater increase
95% CI 0.10 to 9.29
d = 0.6p < 0.05Bonferroni-correctedIn the paper: Results, 'Psychological outcomes: psychological well-being'; Fig. 4C legend- We flipped the sign of the printed interval so that, like the other rows, positive favours 25 mg.
- The paper prints a range of 14 to 70 (Methods, 'Well-being') and a range of 16 to 80 (Fig. 4C legend). No correction was listed when we checked on 2026-10-05. We print 14 to 70, the range the Methods derive from 14 items scored 1 to 5.
- The paper prints this interval as [−9.29, −0.10] beside a positive mean difference of 4.70. The interval appears to be the 1 mg arm minus the 25 mg arm; the paper does not say which way it subtracted.
Cognitive flexibility
Extradimensional shift (EDS) errors, IDED set-shifting task, error rate: errors divided by trials in the EDS phase
0.06fewer errors per trial
95% CI 0.00 to 0.12
d = 0.5 or 0.6p = 0.016FDR + Bonferroni; legend adds outlier correctionIn the paper: Results, 'Psychological outcomes: cognitive flexibility'; Fig. 4D legend- The paper prints 0.5 (Results, 'Psychological outcomes: cognitive flexibility') and 0.6 (Fig. 4D legend). No correction was listed when we checked on 2026-10-05. The two passages may describe different analyses, and the paper does not say which d belongs to this interval, so the figure shows both.
- The lower end of the interval rounds to zero.
- No significant effect of the 1 mg dose on any of these tests. (Fig. 4 legend)
- P values were adjusted within each outcome, not across outcomes. (Discussion)
- Fixed order: everyone took 1 mg first and 25 mg four weeks later, so practice or order effects cannot be fully ruled out. (Methods, 'Study design and participants'; Discussion)
- Cohen's d benchmarks: 0.2 small, 0.5 medium, 0.8 large.
Data table
| Outcome | Mean difference | 95% CI | Cohen’s d | p value | Correction | Where in the paper |
|---|---|---|---|---|---|---|
| Personal insightPsychological Insight Scale (PIS), 0 to 100 visual analogue scale. 25 mg vs 1 mg, each scored one month after that dose (not a change from baseline). | 27.86 points | 18.90 to 36.82 | 1.2 | p < 0.0001 | Bonferroni-corrected | Results, 'Psychological outcomes: psychological insight'; Fig. 4B |
| Well-beingWarwick-Edinburgh Mental Wellbeing Scale (WEMWBS), 14 to 70, 14 items scored 1 to 5. 25 mg vs 1 mg at one month, reported as a greater increase in well-being after 25 mg. | 4.70 points | 0.10 to 9.29 | 0.6 | p < 0.05 | Bonferroni-corrected post hoc comparison | Results, 'Psychological outcomes: psychological well-being'; Fig. 4C legend |
| Cognitive flexibilityExtradimensional shift (EDS) errors, IDED set-shifting task, error rate: errors divided by trials in the EDS phase. One month after 25 mg vs one month after 1 mg. | 0.06 errors per trial | 0.00 to 0.12 | 0.5 or 0.6 | p = 0.016 | FDR across the nine IDED task phases plus Bonferroni within the EDS phase (Results). The Fig. 4D legend adds “outlier corrected, see Figure S18C”; the Results do not mention outlier correction. | Results, 'Psychological outcomes: cognitive flexibility'; Fig. 4D legend |
Personal insight
- Measure
- Psychological Insight Scale (PIS), 0 to 100 visual analogue scale
- Contrast
- 25 mg vs 1 mg, each scored one month after that dose (not a change from baseline)
- Mean difference
- 27.86 points
- 95% CI
- 18.90 to 36.82
- Cohen’s d
- 1.2
- p value
- p < 0.0001
- Correction
- Bonferroni-corrected
- Where in the paper
- Results, 'Psychological outcomes: psychological insight'; Fig. 4B
Well-being
- Measure
- Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS), 14 to 70, 14 items scored 1 to 5
- Contrast
- 25 mg vs 1 mg at one month, reported as a greater increase in well-being after 25 mg
- Mean difference
- 4.70 points
- 95% CI
- 0.10 to 9.29
- Cohen’s d
- 0.6
- p value
- p < 0.05
- Correction
- Bonferroni-corrected post hoc comparison
- Where in the paper
- Results, 'Psychological outcomes: psychological well-being'; Fig. 4C legend
Cognitive flexibility
- Measure
- Extradimensional shift (EDS) errors, IDED set-shifting task, error rate: errors divided by trials in the EDS phase
- Contrast
- One month after 25 mg vs one month after 1 mg
- Mean difference
- 0.06 errors per trial
- 95% CI
- 0.00 to 0.12
- Cohen’s d
- 0.5 or 0.6
- p value
- p = 0.016
- Correction
- FDR across the nine IDED task phases plus Bonferroni within the EDS phase (Results). The Fig. 4D legend adds “outlier corrected, see Figure S18C”; the Results do not mention outlier correction.
- Where in the paper
- Results, 'Psychological outcomes: cognitive flexibility'; Fig. 4D legend
How the studies relate
Where they agree, where they conflict, and why.
The headline conflict (“it rewires the brain” vs “changes are largely absent”) comes from studies of different people: broad network change lasting weeks has been reported in patients; in the healthy-volunteer studies here, lasting change has been narrower (Siegel, exploratory) or largely absent (Lyons). Whether population explains the difference is untested: dose count, psychological support, timing and analysis differ too, and a significant result in one group with a non-significant one in another is not evidence of a difference between groups.
Why this tierTwo different populations and analyses; the field genuinely debates whether durable change is population-specific or a general drug effect.
The studies also differ in what they measure, and structural and functional measures can diverge in both directions: one mouse lab found new spines lasting a month, while a rat study found neuron function changed months later with no structural difference detected. So “rewiring” and “function returned to baseline” need not contradict each other, but the structural evidence here is mainly in rodents, so this split overlaps species, and which pattern holds in people is open.
Why this tierStructural vs functional measures answer different questions on different timescales.
The mouse rewiring is one candidate mechanism for the human network changes, but that is a cross-species inference, not a demonstration in humans.
Why this tierMechanism shown in mice by one lab (Jiang, Shao); human evidence is imaging-level and correlational. Nardou's oxytocin-dependent critical-period mechanism is a rival candidate.
Partly in tension, same population: in a dense-scanning study of seven healthy adults, an exploratory analysis of six suggested one functional change (weaker hippocampus–default-mode coupling) during three weeks of follow-up, where the group study found enduring functional change “largely absent” at a month. Different designs and timepoints; together they are consistent with narrow lasting change, or with changes that fade between a few weeks and a month.
Why this tierSiegel (n = 7 enrolled, 6 in the persistence analysis, uncorrected, many scans each, weeks) and Lyons (28 enrolled, group analysis, one month) ask the same question with different instruments. Separate programs, tied by one shared co-author (Carhart-Harris).
A larger, sponsor-funded, single-dose trial from a separate program (one shared co-author) reports patient effects at the same three-week mark and did not establish a lasting benefit beyond it; Daws's imaging stops at three weeks. The shared horizon is partly by design.
Why this tierGoodwin measures symptoms and followed patients past week 3; Daws measures brain networks and did not image beyond three weeks. Agreement on timescale, not on mechanism.
Same patients, two measures: part of Daws's integration finding comes from a trial where psilocybin did not clearly beat escitalopram on its primary depression score. The integration signal is evidence about the brain, not proof of a better treatment.
Why this tierDaws analyzed imaging from two trials, one of them Carhart-Harris 2021. One program, so this is context, not independent support.
Jiang's network-scale rewiring builds on the same lab's finding that the new spines persist for a month: one lab refining its own result, not an independent replication.
Why this tierShao and Jiang share the senior author (Kwan) and several co-authors.
The most direct human test of the synapse-growth idea so far found no significant overall increase in synaptic density one week after a dose, while mice show more and larger dendritic spines within a day that last a month. Different species, measures and timepoints, and the human study is small; an exploratory setting comparison found a larger frontal change in a therapy-like room than in the scanner, though the room group's own change was not significant.
Why this tierJohansen (human SV2A PET, n = 15, one week) against Shao (mouse two-photon spine imaging, one month). SV2A PET and spine counts are different measures of synapses.
Same healthy-volunteer sample (25 in the re-analysis; Lyons enrolled 28), a different analysis: where the primary report found enduring functional change “largely absent” at one month, a re-analysis finds activity in fronto-striatal-thalamic circuits more dynamic four weeks after 25 mg than four weeks after 1 mg, only a trend against baseline, and calls the evidence weak to moderate. One program re-reading its own data, not a replication.
Why this tierPasquini reuses the Lyons sample and fMRI; Lyons and Carhart-Harris are authors on both.
Different species, timepoint and method: in mice, more spines a month after one dose; in rats given psilocybin or 25CN-NBOH, several months after one dose, changed neuron function with no difference in synaptic density or spine types detected (the abstract does not say whether the structural result holds for psilocybin alone). The rat study's authors read this as “enduring function plasticity rather than structural plasticity”; a late structural nondetection cannot show that earlier structural growth never occurred.
Why this tierKramer (rats, slice electrophysiology and microscopy, months; abstract only) against Shao (mice, two-photon imaging, one month). Separate labs. The structural null is reported for “psychedelic-treated” rats; the abstract does not separate the two drugs.
Around the one-month mark, two-photon imaging found higher spine density in healthy mice, while synaptic protein puncta counts in obese mice detected no significant difference. Different measures, regions (Cg1/M2 for the spine imaging; prelimbic and infralimbic cortex and hypothalamus for the puncta), populations and labs, so this is not a failed replication, and the second study's authors say that, because spine density peaks around day 7, by day 30 a difference may have been too small for their methods to detect.
Why this tierKeenan (obese male mice, PSD-95 and synapsin-1 puncta, 30 days, 5 to 6 mice per group, between groups) against Shao (mice, repeated spine imaging of the same dendrites, about a month, in a subset of four mice). Puncta counts are not spine counts.
Same trial, a different task: alongside the resting-state integration finding, task fMRI in the escitalopram trial's patients shows changed brain responses to musical surprise three weeks after the second session; unlike the integration finding, no significant correlations were detected between the three prespecified ROI responses and anhedonia or music ratings. It adds a measure at the same three-week horizon, not an independent confirmation or a longer follow-up.
Why this tierHarding and part of Daws come from the same trial (NCT03429075) and program; in that trial both scanned three weeks after the second psilocybin session (Daws also used an open-label trial). Harding found no significant correlation between these regions and anhedonia or music ratings.
Posed as a question, not tested as an explanation: could who was dosed (depression patients or healthy volunteers), what was measured (structure or function) and which species account for why these twenty-four sources disagree about lasting change? The last two overlap, because synapse-level structure has been measured almost only in rodents. The sources report heterogeneous, mostly exploratory findings across populations, regimens, species, assays and follow-up intervals, and they do not establish whether persistent human network changes are specific to depression. What prompts the question: global network change in depression patients, imaged up to three weeks after the second of two doses; narrower or weaker lasting change in the healthy-volunteer studies here, which mostly measured at one week to one month (an exploratory, uncorrected analysis in Siegel, with values near baseline in four people revisited 6 to 12 months later; a change significant against the 1 mg scan but only a trend against baseline in the Pasquini re-analysis; functional change “largely absent” in Lyons, apart from some diffusion and modularity signals); and clear lasting synapse-level structural change after one dose shown by one mouse lab, while a rat study detected changed neuron function months after one dose of psilocybin or 25CN-NBOH with no structural difference (not split by drug in the abstract), an obese-mouse study detected no puncta difference at a month, the one human synaptic-density study detected no significant rise at a week, and a diffusion study in cluster headache detected no significant change at a week. Structure and function have come apart in both directions, and single-dose structural results disagree within rodents too. Two questions for the field: is the broad human signal a response of the depressed brain rather than a general effect of the drug, and does it hold outside the one program it comes from, when six of the human papers, resting on three cohorts, come from that program, including both sides of the population contrast (Daws, Lyons), and the two single-dose depression trials count as one program? What would test it: studies that dose patients and healthy volunteers alike and scan both at the same times, and animal studies that measure structure and function in the same animals over months. (Caveats: population is entangled with dose count, psychological support, age, timing, assay and analysis; a significant result in one population and a non-significant one in another is not evidence of a population difference; expectancy is poorly controlled, since only Siegel used a psychoactive control; every human imaging result here comes from a small sample, and several pre-post designs have no placebo arm; brain integration may follow mood improvement rather than drive it; several version 2.2 sources were read from abstracts only; studies before 2024 were not searched for this update; and in the depression-patient imaging studies included here, scans stop at about three weeks after the second dose, while symptoms improved more than with placebo at six weeks in one trial here, and an observational six-month follow-up found both the psilocybin and escitalopram groups still improved, with no significant difference between them, so how long a brain or symptom effect caused by psilocybin lasts is not settled.)
Why this tierPsychDoc's cross-source reading, offered to the field as a question, not asserted as fact.
Our reading, posed as a question, not a verdict
2 automated stress tests (11 October 2026): Revised on 2026-10-11 after an independent automated source check (run outside this repository against the earlier text) found the reading stated as a supported explanation and the patient horizon overstated. A draft revision was then re-tested against all twenty-four v2.2 sources by two automated passes (AI agents) with separate briefs: (1) evidence and confounds, (2) independence, logic and wording. Both returned “survives with required edits”; the edits were applied, among them: the reading posed as an untested question, measure and species named as overlapping, Lyons's persisting diffusion and modularity signals and Siegel's 6 to 12 month revisit named, expectancy and no-placebo designs added to the caveats, Erritzoe described as both arms improved with no difference, the Kramer null kept unsplit by drug, and the program ties (Goodwin and Raison; Siegel; Gudmundsen) disclosed. The agents checked the reading against the claims, bases and author lists recorded here and in the corpus snapshot, not against the papers' full texts, and the final wording was not run through them again. These are automated stress tests, not peer review. Independent expert review is invited and not yet complete. (Earlier passes: two on 2026-09-29 against the nine v2.0 sources; v1's two inline passes, 2026-07-19, covered the five-source wording.)
Checked by AI against the recorded claims of all 24 studies here, not their full texts.
Expert review: invited. Offer to review this reading.
The claims, tiered
Every claim carries its tier, the reason for it, and where it comes from.
- 1PreliminaryLyons 2026
In healthy volunteers, a single 25 mg dose left enduring functional brain changes “largely absent” one month later, though some diffusion-imaging and network-modularity signals persisted; what lasted was mainly psychological: well-being and insight.
Why this tierLyons: within-subjects, 28 enrolled, exploratory, not pre-registered. “Largely absent” is the authors' phrasing.
Would change ifA pre-registered, adequately powered study in healthy volunteers finds enduring functional brain change at one month or later. That would move this from preliminary to active debate; an independent replication of the null would move it toward established.
Predictions resting on this claim:Prediction 1 - 2PreliminaryDaws 2022
In depression patients given two doses with psychological support, psilocybin increased global brain integration (lower network modularity), and the size of that change tracked the antidepressant response.
Why this tierDaws: two trials; correlational; subscription article (facts cited, figures not reused).
Would change ifAn independent research program fails to find increased global integration in depression patients, or finds it without any link to antidepressant response. A second independent replication would move this toward established.
Predictions resting on this claim:Prediction 2 - 3PreliminaryDaws 2022
Those integration changes were seen up to three weeks after the second of two doses; the study did not establish how much longer they last.
Why this tierDaws: fMRI at baseline and ~3 weeks post-dose; longer-term durability not measured.
- 4PreliminaryJiang 2026
In mice, one dose reorganizes the brain-wide inputs to frontal cortex pyramidal neurons in a network-specific way: it strengthens the routing of inputs from perceptual and medial regions, a homolog of the default mode network, to subcortical targets, and weakens inputs that form cortico-cortical recurrent loops. Silencing one presynaptic region during dosing interfered with this rewiring, so the reorganization depends on drug-evoked spiking activity.
Why this tierJiang 2026: monosynaptic rabies tracing of the inputs to frontal cortex pyramidal neurons; per the abstract, silencing a presynaptic region during dosing interfered with the rewiring. The silencing result concerns these traced inputs, not dendritic spines. Spine growth after one dose is the same lab's earlier result (Shao 2021, c-mouse-spines-persist).
Would change ifAn independent lab fails to find the network-specific input reorganization with rabies tracing, or finds that it survives silencing of the presynaptic region during dosing. Either would move the mechanism from preliminary to active debate.
Predictions resting on this claim:Prediction 3 - 5PreliminaryNardou 2023
In mice, psychedelics reopen a “critical period” for social-reward learning, and the window's length is proportional to each drug's acute subjective duration: roughly two weeks for psilocybin, up to four for ibogaine.
Why this tierNardou/Dölen: shared across psychedelics; mechanism via oxytocin-mediated LTD and extracellular-matrix remodeling. Durations are the paper's mouse findings.
- 6PreliminaryNardou 2023, Lyons 2026, Shao 2021
The popular “psilocybin opens a four-week window that rewires your brain” collapses different things: it appears to borrow ibogaine's four-week mouse figure (psilocybin's was ~2 weeks) or to stretch a one-month mouse spine result, and it merges a behavior-specific mouse finding with human brain imaging, none of which is the same claim.
Why this tierThe mouse critical-period result is about social-reward learning, not general brain rewiring; the four-week figure is ibogaine's, not psilocybin's; human durable functional change is modest at best (Lyons).
- 7PreliminarySiegel 2024
In seven healthy adults scanned repeatedly before, during and after a 25 mg dose, psilocybin acutely desynchronized brain networks far more than an active control (methylphenidate). Most changes faded; an exploratory analysis in six of them suggested reduced hippocampus–default-mode coupling during the three-week follow-up.
Why this tierSiegel: precision functional mapping (many repeated scans of a few people rather than one scan of many); n = 7; the only study here with a psychoactive control. Washington University group; Carhart-Harris is one co-author of 33, so it counts as a separate program tied to the Imperial one. Participants were scanned for three weeks after the dose. The persistence analysis used six participants and 186 repeated observations pooled over days 1 to 21: anterior hippocampus functional-connectivity change, linear mixed-effects estimate 0.095 (95% CI 0.032 to 0.168), P = 0.0033 uncorrected, in a region chosen by a screen at P < 0.05. That statistic tests the region's change metric, while the hippocampus–default-mode decrease is shown in the paper's Fig. 5c–d, and it does not establish persistence on each day or at day 21. At an open-label revisit 6 to 12 months later, values appeared near baseline in four people, a sample not powered for small changes.
- 8PreliminaryGoodwin 2022
In the largest trial here (233 people with treatment-resistant depression), a single 25 mg dose reduced depression scores more than a 1 mg control at three weeks; 10 mg did not separate from control, and a lasting benefit beyond three weeks was not established.
Why this tierGoodwin: phase 2b, randomized, double-blind, three doses (25, 10, 1 mg) with psychological support, after participants stopped their antidepressants; primary outcome MADRS change at week 3. Sponsor-funded (COMPASS Pathways). Adverse events, including suicidal ideation or self-injury, occurred in every dose group. A clinical outcome, not brain imaging.
- 9PreliminaryCarhart-Harris 2021
In a six-week double-blind trial of 59 people with moderate-to-severe depression, two 25 mg doses of psilocybin did not significantly beat daily escitalopram on the primary depression score; secondary measures leaned toward psilocybin but were not corrected for multiple comparisons.
Why this tierCarhart-Harris 2021: phase 2, active comparator (escitalopram plus 1 mg psilocybin); primary outcome QIDS-SR-16 at week 6, which may be short for escitalopram to reach full effect. A clinical outcome, not imaging. Included because part of Daws's imaging comes from this trial's patients.
- 10PreliminaryShao 2021
In mice, a single dose increased the density and size of dendritic spines in frontal cortex within a day, and the higher spine density was still measurable about a month later.
Why this tierShao: chronic two-photon imaging of the same dendrites in living mice before and after one dose, in medial frontal cortex (Cg1/M2); the month follow-up (day 34) imaged a subset of four mice. Kwan lab: the same lab as Jiang 2026, so the two mouse rewiring papers are one program.
- 11EstablishedLyons 2026, Daws 2022, Carhart-Harris 2021, Pasquini 2026, Harding 2025, Erritzoe 2024
Six of the human papers here come from one research program (Carhart-Harris and colleagues) and draw on three cohorts, with explicit dataset reuse and shared investigators, so they are not six independent replications; two other human studies (Siegel, Goodwin) each list him as one co-author among many.
Why this tierLyons, Daws and the 2021 escitalopram trial share a lead or senior author (Carhart-Harris) and several co-authors (Erritzoe, Nutt, and others), and part of Daws's imaging comes from that trial's patients. Pasquini re-analyses the Lyons sample, and Harding re-analyses the escitalopram trial; both list Carhart-Harris and Nutt. Erritzoe 2024 follows up the escitalopram trial's patients for six months, with Carhart-Harris as senior author and Nutt among the authors. The six papers rest on three samples (the Lyons volunteers, the escitalopram trial, and Daws's open-label trial). Siegel (33 authors) and Goodwin (74 authors) each list Carhart-Harris mid-list. Verifiable authorship and data facts. Shared authorship alone does not show shared samples, and separately recruited cohorts within one program still add participant data. (Version 2.2 changed “Three” to “Six” when Pasquini, Harding and Erritzoe were added.)
- 12PreliminaryNovelli 2025
A large multimodal human study (PsiConnect, 62 participants, follow-up to one year) is mapping psilocybin's effects across imaging methods, but it is a preprint, and not yet a settled result.
Why this tierbioRxiv preprint (not peer-reviewed), CC-BY-NC-ND; a dataset/methods contribution rather than a specific finding.
- 13PreliminaryJohansen 2026
In 15 healthy adults, one dose did not significantly increase synaptic density one week later overall, measured by SV2A PET in frontal cortex and hippocampus. In an exploratory comparison, participants dosed in a therapy-like room showed a greater frontal increase than those dosed in an MRI scanner; the hippocampal difference was smaller, with an interval that included zero.
Why this tierJohansen: [11C]UCB-J PET at baseline and one week after 0.3 mg/kg psilocybin, in an open-label, single-arm study with no placebo. The VT analysis, run at an interim look on the 12 participants with complete arterial blood data, found no significant increase (mean change: frontal cortex 0.3 mL/cm3, SD 2.6; hippocampus 0.3 mL/cm3, SD 2.0; one-sided p = 0.29 and 0.33), and the study was stopped for futility; BPND, computed for all 15, showed no significant increase either (mean change: frontal cortex −0.01, SD 0.35; hippocampus 0.01, SD 0.28). Setting difference in the change in VT: frontal cortex 3.0 mL/cm3 (95% CI 0.4 to 5.5), hippocampus 1.9 mL/cm3 (95% CI −0.3 to 3.9); the authors call it preliminary and hypothesis-generating. With no placebo arm, the authors note they may have underestimated an increase, because other SV2A studies saw drops at a second scan. The room group's own change in VT: frontal cortex 1.1 mL/cm3 (95% CI −0.5 to 2.7), hippocampus 0.8 mL/cm3 (95% CI −0.5 to 2.1). The Methods list participants 1 to 5 as dosed in the scanner and 6 to 15 in the room; the main text does not say how setting was allocated. SV2A density is a marker of synaptic density in living people, not a count of dendritic spines.
Would change ifA larger or independently replicated PET study finding a significant overall increase in synaptic density after one dose would move the human question to active debate. A preregistered test of the setting effect would show whether the subgroup difference holds.
- 14PreliminaryPasquini 2026
Re-analysing the same healthy volunteers as Lyons, a study that also used computational modelling found activity in fronto-striatal-thalamic circuits more dynamic four weeks after 25 mg than four weeks after the 1 mg control dose, but only a trend against the pre-dose baseline; the authors call the evidence weak to moderate.
Why this tierPasquini: secondary analysis of the Lyons trial's resting fMRI, 25 psychedelic-naive adults in a fixed order (1 mg, then 25 mg four weeks later; no placebo, no randomized order). Dynamic functional homogeneity across 28 fronto-striatal-thalamic regions was lower four weeks after 25 mg than four weeks after 1 mg (t(24) = 2.87, p = 0.008) and trended lower than baseline (t(24) = 1.92, p = 0.06); the paper reads lower homogeneity as more dynamic, more variable activity across a scan, and its Methods say FDR correction “was used to adjust p-values, unless specified otherwise”, without saying which applies to these t-tests. Whole-brain homogeneity fell at both later scans, which the authors attribute to order effects. The modelled drop in structure-function coupling was stable across repeated simulations, which the authors say “do not represent independent biological samples”; its group-level permutation test was a trend (one-sided p = 0.064; the observed difference was smaller than 90% of permuted differences). The effective-connectivity results rest only on stability statistics across simulations. Same sample and program as Lyons (Lyons and Carhart-Harris are co-authors), so not independent. Full text read; CC BY-NC 4.0, cited only.
- 15PreliminaryBhagavan 2026
In ten healthy volunteers who each received three low-to-moderate doses (5 to 20 mg) in random order (a preprint, read from its abstract), brain connectivity one week after a dose showed one dose-dependent increase within a network that survived correction, and none of the 77 nominal dose-dependent changes in single connections did; dose-adjusted changes in conscious state were linked to wider connectivity changes, many surviving correction at the network level.
Why this tierBhagavan: medRxiv preprint, not peer reviewed. Ten healthy volunteers each received three doses between 5 and 20 mg in randomized, blinded order at least a week apart; resting fMRI at baseline and one week after a single dose (registered ACTRN12621000560897). Per the abstract: 77 dose-dependent edge changes (76 increases, 1 decrease, of 1275) with none surviving correction; one dose-dependent between-network increase (of 21) and one within-network increase (of 7), the latter surviving correction; dose-adjusted changes in conscious state were associated with connectivity change, many surviving correction. Abstract only: the full text was unreachable, so which dose in the sequence each scan followed, possible carry-over from earlier doses, the correction procedure, the network involved and the effect sizes are not checked.
- 16PreliminaryMadsen 2024, Brendstrup-Brix 2026
In a small open-label trial in chronic cluster headache, with three doses of 0.14 mg/kg a week apart, a change in hypothalamic connectivity tracked how much attacks fell (10 patients in the trial), and a later analysis of the same trial detected no statistically significant change in brain microstructure one week after the last dose (11 patients at baseline, 8 with complete follow-up).
Why this tierMadsen 2024 (abstract only; full text unreachable): 10 patients, 0.14 mg/kg in weeks five, six and seven, fMRI the day before the first dose and one week after the last; attacks fell 31% on average (SD 31), and the change in hypothalamic-diencephalic connectivity correlated with the change in attack frequency (R = -0.81, pFWER = 0.03); how many patients entered that correlation is not checked. Brendstrup-Brix 2026 (publisher full text checked during the 2026-10-11 review; this session could not reach it): a post hoc analysis of the same EPOCH trial (NCT04280055), diffusion MRI before and one week after, 11 patients at baseline and 8 with complete follow-up, analysed with mixed models; all six Holm-adjusted microstructure comparisons had p = 1.00, a nondetection rather than evidence of no change; psilocybin “was not associated with statistically significant changes in brain microstructure or water diffusivity”, though seven of the eight showed descriptive decreases in white-matter diffusivity and intra-neurite volume fraction. Exactly which patients are in both analyses is not checked. No placebo. One Copenhagen program, the same as Johansen 2026 (Knudsen and Madsen are authors on all three).
- 17PreliminaryHarding 2025
In depression patients from the escitalopram trial, task fMRI three weeks after the second psilocybin session showed a greater pre/post decrease in surprise-related ventromedial prefrontal and right angular gyrus responses than escitalopram, and, within the psilocybin group, more activity in sensory regions, an increase that did not differ significantly from escitalopram.
Why this tierHarding: secondary analysis of the phase II psilocybin versus escitalopram trial (NCT03429075), 22 psilocybin and 19 escitalopram patients with usable fMRI, scanned the day before the first dose and six weeks later, three weeks after the second psilocybin session. Ventromedial prefrontal treatment-by-time interaction F(1,39) = 7.074, p = 0.0113; the within-group decrease after psilocybin t(21) = 2.195, p = 0.0395, with no correction across the three regions of interest described. The right angular gyrus difference comes from the whole-brain contrast of pre/post change between groups; the within-psilocybin decrease was in the left angular gyrus. No significant change in the nucleus accumbens or superior temporal gyrus, and no significant correlations were detected between the three prespecified ROI responses and anhedonia or music ratings; whole-brain maps cluster-corrected; baseline vmPFC differed between groups at trend level (p = 0.081). Surprise-related affective ratings showed no significant change after psilocybin (they fell after escitalopram). A published correction changed the abstract to “decreased activation in the ventromedial prefrontal cortex”; this claim follows the correction. One song, one task. Same trial and program as Carhart-Harris 2021 and part of Daws 2022. Full text read; CC BY 4.0, cited only.
- 18PreliminaryFarré-Colomés 2026, Sabbah 2026
Two 2026 systematic reviews flag limits in human follow-up imaging: one, covering studies published to July 2024, found follow-up scans lacking in most psilocybin fMRI studies, with lasting effects reported up to four weeks in those that had them; the other, in depression, grouped some network changes as “Longer-term changes (5+ weeks)” without saying in its abstract whether that is when scans were taken, and warned that many studies reuse overlapping datasets.
Why this tierFarré-Colomés (full text read): 36 articles from 20 datasets, published between February 2012 and July 2024; “follow-up scanning timepoints were lacking in most of the studies”, and studies with follow-up scans suggest effects “lasting up to 4 weeks after intake”; PRISMA, not preregistered, no named risk-of-bias tool. Sabbah (abstract only, full text unreachable): 11 studies in depression, PROSPERO-registered; early (0 to 4 weeks) changes included lower modularity and higher integration, and “Longer-term changes (5+ weeks)” included higher prefronto-parietal and salience-network connectivity; “Many studies reused overlapping datasets with high exploratory flexibility and risk of bias.” Which studies carry Sabbah's 5+ week finding, and whether it refers to scan or outcome timing, cannot be checked without its full text. Farré-Colomés's search ended in March 2025 and covered publications to July 2024, so its finding is a coverage statement, not a ceiling on the current literature; its use of “follow-up” is ambiguous, since Daws reports scans three weeks after the second dose. Two separate teams.
- 19PreliminaryKramer 2026
In rats, a single dose of psilocybin or of the 5-HT2A agonist 25CN-NBOH reduced immobility in a forced swim test for at least three months; several months after treatment, prefrontal layer 5 neurons still showed changed resting potential, firing and synaptic excitation after either drug, while no difference in synaptic density or spine types was detected between control and psychedelic-treated rats; the abstract does not say whether that structural result holds for psilocybin on its own.
Why this tierKramer (Nichols lab): per the abstract, there were “no overt behavioral differences between psilocybin and 25CN-NBOH treated animals” and functional plasticity “was evident for both psychedelics”; the microscopy and gene-expression nulls compare “control and psychedelic-treated” animals, and the abstract does not say whether psilocybin was tested on its own for them. Brain-slice electrophysiology found functional plasticity “several months after treatment”; microscopy of the recorded neurons found no differences in synaptic density or spine classification, and gene expression for several synaptic markers did not differ. Abstract only: the full text was unreachable, so animal and cell numbers, sampling dates, multiplicity and any drug-specific structural tests are not checked. The longest-lasting change after a single dose reported in this synthesis, from a lab separate from the mouse spine studies.
- 20PreliminaryGudmundsen 2026
In rats, one week after a single dose, compared with the same rats before dosing, psilocybin on its own changed relative brain glucose uptake in few measures: uptake rose in the insula and the across-rat correlation between prefrontal and insula uptake strengthened, and no whole-brain cluster survived correction for psilocybin alone; the paper's headline one-week hypometabolism pools psilocybin with LSD and 2C-B.
Why this tierGudmundsen: 12 Long Evans rats of both sexes per drug group (11 analysed for LSD), [18F]FDG-PET at baseline, acutely and one week after 1 mg/kg psilocybin given under the skin, each group compared with its own baseline (no drug-versus-saline contrast described; the saline cohort showed no change between repeated scans). Uptake is normalized to the whole-brain mean, so it is relative. Insula mean change in normalized uptake 0.16 (adjusted p < 0.05); prefrontal-insula covariance (a correlation across rats, not a within-brain connection) change ΔZ = 1.53 (adjusted p = 0.04); thalamus-prefrontal change not significant after correction (adjusted p = 0.61). “Psilocybin produced no acute or persistent clusters surviving FDR correction.” Correction families differ: region-of-interest adjustments cover the specified comparisons, while voxel analyses use separate FDR and FWE procedures. The paper's Results (“despite not reaching significance in individual drug contrasts”) and Discussion (“significantly reduced for psilocybin”) disagree about psilocybin's own change in the pooled one-week clusters. Full text read; CC BY-NC-ND 4.0, cited only.
- 21PreliminaryKeenan 2026
In diet-induced obese male mice given one dose, no statistically significant treatment difference was detected in synaptic protein puncta counts (PSD-95, synapsin-1) in prefrontal cortex and hypothalamus 30 days later.
Why this tierKeenan: male C57BL/6J mice made obese on a high-fat diet, one 1 mg/kg intraperitoneal dose, then either kept on the high-fat diet or switched to low-fat chow; brains taken 30 days later; 5 to 6 mice per group, between groups rather than repeated imaging. “Psilocybin had no influence on positive puncta of synapsin-1, PSD-95 or co-localisation of both proteins (i.e., synapses)” in the three regions. The authors note that spine density peaks around day 7, so by day 30 a difference “may not have been substantial enough to be detected with the methods used here”. Puncta counts are not spine counts, and a nondetection does not show equivalence or rule out smaller effects. Full text read; CC BY-NC-ND 4.0, cited only.
- 22PreliminarySahoo 2026, García-Cabrerizo 2025
In two studies, repeated dosing in adolescent rodents was followed by brain differences weeks to months later whose meaning is unclear: mice dosed five times in adolescence showed exploratory differences in normalized regional brain volumes, diffusion and connectivity on MRI as adults, and in rats dosed daily for a week, the higher dose (1 mg/kg) raised a hippocampal progenitor-cell marker (NeuroD1) 16 days after treatment, which was associated with forced-swim escape behaviour measured the day before.
Why this tierSahoo (full text read): 28 mice, an approximate dose of 3.0 mg/kg by gavage every other day on postnatal days 40 to 50; structural and diffusion MRI at postnatal day 85, resting-state connectivity at day 107 and odour-evoked BOLD at day 176, one measurement per modality rather than repeated tests of persistence. Exploratory differences: normalized regional volumes lower in both sexes (males p < 0.001, females p < 0.05) and pooled diffusion measures rose (p < 0.0001); no area-level sex-by-treatment effect survived FDR correction, no standardized effect sizes are given, the regional tests state no correction and appear to pair brain areas rather than animals, the resting-state sample (10 versus 11) pooled the sexes, and the abstract and protein-method timeline conflict with the imaging dates. Funded by Ekam Imaging, in which two authors hold a partnership interest. García-Cabrerizo (abstract; Methods and Fig. 5 checked during the 2026-10-11 review, complete methods not checked): adolescent Sprague-Dawley rats of both sexes, 0.3 or 1 mg/kg by mouth daily for 7 days; on day 16, NeuroD1 was higher after 1 mg/kg (p = .002) but not significantly after 0.3 mg/kg (p = .123); forced-swim behaviour was measured on day 15; across 39 animals pooled over sexes, NeuroD1 correlated with escape behaviour (r = .418, p = .008). NeuroD1 marks progenitor cells: this is not evidence of new mature neurons or of mediation, and multiplicity is not checked. Repeated dosing in development, not one adult dose; two separate labs.
- 23PreliminaryRaison 2023, Erritzoe 2024
In patients, symptoms have been followed for longer than the brain scans in the patient imaging studies here. In a randomized trial of 104 adults with major depression, one 25 mg dose with psychological support lowered depression scores more than an active placebo (niacin) six weeks later. A six-month follow-up of the escitalopram trial found both groups still improved, with no significant difference between them, but it was observational, with missing data and further treatment allowed, so it cannot show how long a benefit caused by psilocybin lasts.
Why this tierRaison (abstract only; full text unreachable): phase 2, 11 US sites, 104 adults randomized 1:1 (51 psilocybin 25 mg, 53 niacin 100 mg), both with psychological support, after any psychotropic medication was tapered; primary outcome the change in central rater-assessed MADRS from baseline to day 43, mean difference −12.3 (95% CI −17.5 to −7.2; P < .001); at day 8, −12.0 (95% CI −16.6 to −7.4). More participants on psilocybin had a sustained response, but not remission. Psilocybin had higher rates of overall and severe adverse events and no serious treatment-emergent ones. Assessments ended at day 43; the sponsor is not named in the abstract and was not checked. Erritzoe (full text read; CC BY-NC 4.0, cited only): observational six-month follow-up of the Carhart-Harris 2021 trial (two 25 mg doses against six weeks of escitalopram, both with support); 25 of 30 and 21 of 29 patients completed; QIDS-SR-16 between-condition difference at six months 1.51 (95% CI −1.35 to 4.38; p = 0.311); functioning, connectedness and meaning in life favoured psilocybin. Patients had no restrictions on psychiatric care during follow-up, and the authors call the results descriptive, citing limited power, missing data, possible further treatment and self-report. Erritzoe was excluded from the 2026-10-10 screen, whose rules required a brain measure; it is added here under the synthesis's own criteria, which include clinical outcomes. Clinical outcomes, not brain imaging; same trial and program as Carhart-Harris 2021, Daws and Harding.
Predictions
What we expect new studies to find, and which results would count for or against each.
Prediction 1
Draft prediction. Not yet a committed test.We expect. In healthy adults given one 20 to 30 mg dose of psilocybin, three named measures of resting brain networks will not differ by a medium or larger amount from those of people given an active placebo, one month later. Concretely: a randomized study with an active placebo will find no difference of medium size or larger (|d| of 0.5 or more, where d is the between-group difference divided by the pooled standard deviation) between the groups 28 to 42 days after the dose, on three resting-state fMRI measures: whole-brain network modularity, fronto-striatal-thalamic dynamic homogeneity, and hippocampus to default-mode connectivity.
Why we think so. The one study in the record that scanned healthy volunteers at this point against a control scan, Lyons 2026 (28 enrolled, fixed order, exploratory, not pre-registered), found lasting functional change "largely absent" at one month. What lasted was mainly psychological: well-being and insight. Screened, abstract only: McCulloch 2021 reports lower executive-control-network connectivity one week after a dose and no statistically significant connectivity changes at three months.
What would count against it. A preregistered randomized study with an active placebo, outside the Imperial program, finds a between-group difference on one of the three measures, at a prespecified visit within days 28 to 42. Its multiplicity-adjusted 95% interval for d lies wholly above 0.5 or below −0.5.
What would support it. Such a study finds, at its prespecified visit within days 28 to 42, that the 90% interval for d lies wholly between −0.5 and 0.5 on all three measures. A result that meets neither line is inconclusive.
Already pulling the other way.
- Pasquini 2026, a re-analysis of the Lyons volunteers, found fronto-striatal-thalamic activity more dynamic four weeks after 25 mg than after 1 mg. Against baseline it was only a trend, and the authors call the evidence weak to moderate. Same people, same program: not a replication.
- In Lyons, one amygdala connectivity measure differed from the 1 mg scan at one month. Those voxels were picked by that same contrast. The supplement does not clearly identify the comparator for its reported effect size.
- At one month, Lyons reported lower average modularity than at baseline. The difference from the 1 mg scan was smaller and not statistically significant. Some diffusion changes also persisted; diffusion is outside this prediction.
- Screened, abstract only: Barrett 2020, an open-label pilot study, reports resting-state changes one week and one month after a dose.
Why it matters. If healthy brains settle back while depressed brains change (prediction 2), the drug's lasting brain effect may depend on the state of the brain it meets. That is the record's central open question. If this prediction fails, at least one named measure can differ in healthy adults one month after a dose. That would weaken a strict patient-versus-healthy distinction.
Dates. First stated 24 September 2026, as what would change the record's healthy-volunteer claim. Written as a testable prediction 24 October 2026. This wording 8 November 2026.
Rests onClaim 1Prediction 2
Draft prediction. Not yet a committed test.We expect. In a new study outside the Imperial program, adults with major depression receive one of Daws's two-dose regimens with psychological support. We expect lower average resting-state network modularity (more integrated networks) at a prespecified scan 1 to 22 days after the second dose than before dosing. Larger falls should track greater improvement on the study's main depression measure at its prespecified follow-up.
Why we think so. Daws 2022 reported this in two Imperial cohorts. In an open-label trial (10 mg, then 25 mg a week later), average modularity was lower one day after the 25 mg dose. Larger falls went with greater improvement in Beck Depression Inventory scores at six months. In a randomized trial against escitalopram (25 mg twice, three weeks apart), average modularity was lower three weeks after the second dose, and the fall went with improvement at that visit (reported at P = 0.025 on a one-tailed test). The escitalopram arm showed no statistically significant change in modularity. The change did not differ significantly between arms.
What would count against it. Such a study finds increased average modularity, or finds that larger falls track less improvement, with a 95% interval excluding zero. An inconclusive estimate would not count against it.
What would support it. Such a study finds lower average modularity after dosing than before, and finds that larger falls track greater improvement, each with a 95% interval excluding zero. If neither part meets the line above, a precise estimate near zero on either part, with its 95% interval including zero, would still weaken the prediction. We have not yet set how near zero counts.
Already pulling the other way. No contrary result is known to the record. The authors say their design cannot show the drug alone caused the change. Both cohorts come from one program, and both samples are small (16 and 22 patients in the imaging analyses). Screened, abstract only: Doss 2021, an open-label depression study from a different program, reports changed brain dynamics one week after psilocybin therapy, measured differently. It neither confirms nor contradicts this prediction.
Why it matters. If the change appears in patients and tracks recovery, it may be part of how people get better rather than a general drug effect on every brain. It could also follow the mood improvement rather than drive it. This prediction cannot tell those apart. A study that measures both at several points could.
Dates. First stated 24 September 2026, as what would change the record's patient-integration claim. Written as a testable prediction 24 October 2026. This wording 8 November 2026, correcting the October draft, which wrongly called the six-month depression score the trial's primary endpoint.
Rests onClaim 2Prediction 3
Draft prediction. Not yet a committed test.We expect. In adult mice, the shift that one dose of psilocybin causes in which regions send input to frontal-cortex pyramidal neurons, as measured by rabies tracing, depends on activity in those input regions at the time of dosing. Silencing an input region while the drug acts will stop that region's inputs from shifting.
Why we think so. Jiang 2026 traced the inputs to frontal pyramidal neurons and found one dose strengthens routes from perceptual and default-mode-like regions to subcortical targets and weakens cortico-cortical loops. Silencing retrosplenial cortex during dosing removed the psilocybin-related increase in its share of traced inputs to frontal pyramidal tract neurons. Silencing also reduced labelling without psilocybin. One lab, reported once.
What would count against it. A lab outside the Kwan program verifies silencing during dosing and reproduces the unsilenced shift. The drug still shifts traced inputs under silencing, relative to silenced vehicle controls, with a 95% interval excluding zero. A precise failure to reproduce the unsilenced effect would challenge the underlying effect. An inconclusive result settles neither.
What would support it. Such a lab reproduces the unsilenced shift and finds that silencing shrinks it toward zero. It compares two drug-minus-vehicle differences in the silenced region's share of traced inputs: one under silencing and one without. The 95% interval for the gap between them excludes zero, in the direction of a smaller shift under silencing. Under silencing, the drug-minus-vehicle difference has a 95% interval that includes zero and lies wholly within a range around zero set in advance. We have not yet set that range, so this rule is not yet complete.
Already pulling the other way. No contrary result in this assay is known to the record. Screened, abstract only: Lu 2026 found replicable acute behavioural effects across five labs, but no replicable improvement in the tested anxiety-like, depression-like or fear-extinction outcomes 24 hours after dosing. That is behaviour, not wiring, but it is a reason to want this finding repeated outside one lab.
Not part of this prediction. Shao 2021 imaged spine growth in the same region after one dose. Neither Shao 2021 nor Jiang 2026 tested whether silencing during dosing prevents that spine growth. Jiang's silencing experiment measured traced inputs, not spines. That is a separate, open question.
Why it matters. If the drug rewires mainly the circuits that are active while it acts, then what the brain is doing during a dose could shape what changes. In mice that is a testable mechanism. Whether it carries over to people, and to what happens during a therapy session, is untested.
Dates. First stated 24 September 2026, as what would change the record's mouse-mechanism claim. That line was corrected on 24 October 2026 to say what Jiang measured (traced inputs, not spines). Written as a testable prediction 24 October 2026; this wording, narrowed to traced inputs, 8 November 2026.
Rests onClaim 4
Limitations
Always visible. Never collapsed.
- Twenty-four sources: five chosen by hand to span the debate, four added from the 2026-09-28 citation-graph scan, one added on 2026-10-05 as contrary evidence on human synapse growth, a clinical trial and an observational follow-up added on 2026-10-11 on how long symptoms have been followed, and twelve added on 2026-10-10 after screening the scan's 161 candidates from 2024 to 2026 and an OpenAlex and Europe PMC search for brain measures a week or more after dosing. Not a systematic review: screening was AI-assisted, fifteen candidate records (twelve distinct studies) await a full-text check, and years before 2024 were not searched for this update; Farré-Colomés lists earlier imaging studies with follow-up scans, which are not included here.
- The twenty-four sources are not twenty-four independent single-dose experiments: two are systematic reviews (Farré-Colomés, Sabbah), four report clinical outcomes only (Goodwin, Carhart-Harris 2021, Raison, Erritzoe), several reuse a sample (Daws in part, Pasquini, Harding, Erritzoe, Brendstrup-Brix), several gave repeated doses (Daws, Carhart-Harris 2021, the cluster headache trial, Bhagavan, Sahoo, García-Cabrerizo), and two are preprints (PsiConnect, Bhagavan).
- Several version 2.2 claims rest on abstracts because the full texts were unreachable when screened; their numbers are the abstracts' own, and each such claim says so.
- Six human papers from one research program draw on three cohorts, two Copenhagen papers report the same cluster headache trial, the two single-dose depression trials (Goodwin, Raison) count as one program, and both mouse rewiring studies come from one lab. Papers that reuse a sample are not independent replications; shared authorship alone does not show shared samples.
- Cross-species and cross-population comparison is interpretive: mouse mechanism does not demonstrate the human mechanism, and patient findings need not generalize to healthy people.
- The clinical trials (Goodwin, Carhart-Harris 2021, Raison) and Erritzoe's follow-up measure symptoms, not brain change. They say how long symptoms have been followed, not whether the brain rewired, and the six-month follow-up is observational.
- Population is confounded with protocol: the depression-patient imaging followed two doses with psychological support and was measured at up to three weeks, and the cluster headache imaging followed three doses and was measured one week after the last; most healthy-volunteer studies gave one dose (Bhagavan gave three) and measured at one week (Johansen, PET; Bhagavan), weeks (Siegel, with a 6 to 12 month revisit of four people) or one month (Lyons, Pasquini).
- Expectancy: only Siegel used a psychoactive control. A 1 mg comparison dose is easy for participants to recognize, which can inflate effects.
- Daws, both NEJM trials, Jiang, PsiConnect and Shao are cited only (subscription, non-commercial, no-derivatives, or license not yet checked). Siegel and Johansen are CC BY 4.0 but cited only. Every version 2.2 source is cited only, including Raison (license not checked) and Erritzoe (CC BY-NC). No figure from any of them is reproduced.
- No therapeutic or clinical-use claim is made; this is a communication of evidence, not medical advice.
Open questions
What would change our mind, and what we are asking the field.
- Is durable human “rewiring” specific to the depressed brain rather than a general property of the drug?
- How much of the human evidence is independent, when six papers from one program draw on three cohorts?
- Where structural and functional measures diverge (structure persisting while function resets, or, in rats, the reverse), what does each pattern mean for the brain and for behaviour?
- Will a large, longer study (PsiConnect, to one year) find durable functional change that smaller studies were underpowered to detect?
- Does the narrow change suggested in healthy brains (weaker hippocampus–default-mode coupling, from an exploratory analysis) track anything people feel or do?
- Does brain integration in patients drive their improvement, or follow it?
- Does the lasting change in neuron function seen in rats months after one dose of psilocybin or 25CN-NBOH, with no structural difference detected at the sampled follow-up, hold for psilocybin on its own and in other labs, and is there a human counterpart?
- Will larger, independent, adequately controlled studies scan people again months after a dose?
Sources and provenance
License, data, funding and conflicts for every paper this synthesis reads. Each source card shows how deeply it was read and how that was checked.
Lyons 2026
Human brain changes after first psilocybin use
Lyons, T., Spriggs, M., …, & Carhart-Harris, R. L. · Nature Communications, 2026
- Identifier
- doi:10.1038/s41467-026-71962-3 · PMC13144397
- License
- CC BY 4.0: figures may be rebuilt with attribution.
- Data
- Source Data: self-report, behavioral, processed EEG and MRI. (CC BY 4.0) · Raw imaging on request (academic, non-commercial).
- Conflicts
- R. L. Carhart-Harris advises Atai Beckley, Otsuka, Entropy Neurodynamics; D. J. Nutt advises COMPASS Pathways and others.
- Corrections
- None known.
- Reading
- Read in partRecorded before the two-model checking and signing process.
Daws 2022
Increased global integration in the brain after psilocybin therapy for depression
Daws, R. E., Timmermann, C., …, & Carhart-Harris, R. · Nature Medicine, 2022
- Identifier
- doi:10.1038/s41591-022-01744-z
- License
- All rights reserved: cited only, figures not reproduced.
- Funding
- Medical Research Council; NIHR; EPSRC; Academy of Medical Sciences
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Read in partRecorded before the two-model checking and signing process.
Jiang 2026
Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks
Jiang, Q., Shao, L.-X., …, & Kwan, A. C. · Cell, 2026
- Identifier
- doi:10.1016/j.cell.2025.11.009 · PMC12695013
- License
- CC BY-NC 4.0: cited only, figures not reproduced.
- Data
- Analysis code and region-level data. (GPL-3.0), source
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Read in partRecorded before the two-model checking and signing process.
Nardou 2023
Psychedelics reopen the social reward learning critical period
Nardou, R., Sawyer, E., …, & Dölen, G. · Nature, 2023
- Identifier
- doi:10.1038/s41586-023-06204-3 · PMC10284704
- License
- CC BY 4.0: figures may be rebuilt with attribution.
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Read depth not recordedRecorded before the two-model checking and signing process.
Novelli 2025
PsiConnect: A Multimodal Neuroimaging Study of Psilocybin-Induced Changes in Brain and Behaviour
Novelli, L., Stoliker, D., …, & Razi, A. · bioRxiv (preprint), 2025
- Identifier
- doi:10.1101/2025.04.11.643415
- License
- CC BY-NC-ND 4.0: cited only, figures not reproduced.
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Read depth not recordedRecorded before the two-model checking and signing process.
Carhart-Harris 2021
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., …, & Nutt, D. · New England Journal of Medicine, 2021
- Identifier
- doi:10.1056/NEJMoa2032994
- License
- All rights reserved: cited only, figures not reproduced.
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Read depth not recordedRecorded before the two-model checking and signing process.
Goodwin 2022
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., …, Carhart-Harris, R. L., …, Dunlop, B. W., … Malievskaia, E. · New England Journal of Medicine, 2022
- Identifier
- doi:10.1056/NEJMoa2206443
- License
- All rights reserved: cited only, figures not reproduced.
- Funding
- COMPASS Pathways (trial sponsor)
- Conflicts
- Sponsored by COMPASS Pathways, which develops the COMP360 psilocybin tested; several authors are company employees.
- Corrections
- None known.
- Reading
- Read depth not recordedRecorded before the two-model checking and signing process.
Shao 2021
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., …, & Kwan, A. C. · Neuron, 2021
- Identifier
- doi:10.1016/j.neuron.2021.06.008
- License
- Unknown: cited only, figures not reproduced.
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Read in partRecorded before the two-model checking and signing process.
Siegel 2024
Psilocybin desynchronizes the human brain
Siegel, J. S., Subramanian, S., …, Raison, C. L., …, Carhart-Harris, R. L., … Dosenbach, N. U. F. · Nature, 2024
- Identifier
- doi:10.1038/s41586-024-07624-5 · PMC11291293
- License
- CC BY 4.0: figures may be rebuilt with attribution.
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Read in partRecorded before the two-model checking and signing process.
Johansen 2026
Psilocybin’s effect on human brain synaptic plasticity
Johansen, A., Plavén-Sigray, P., Madsen, M. K., …, & Knudsen, G. M. · Translational Psychiatry, 2026
- Identifier
- doi:10.1038/s41398-026-04285-y
- License
- CC BY 4.0: figures may be rebuilt with attribution.
- Funding
- Innovation Fund Denmark; Independent Research Fund Denmark; Rigshospitalet's Research Council; Swedish Research Council; Lundbeck Foundation; COMPASS Pathways PLC supported one author's salary and, per the paper, had no other relation to the study
- Conflicts
- G. M. Knudsen: speaker for Cybin and H Lundbeck, and consultant for Sanos, Onsero, Pangea, Gilgamesh, Seaport and Abbvie, within the last three years (per the paper). M. K. Madsen: scientific advisor to Lobe Sci (per the paper).
- Corrections
- None known.
- Reading
- Read in partRecorded before the two-model checking and signing process.
Pasquini 2026
Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits
Pasquini, L., Vohryzek, J., Escrichs, A., Perl, Y. S., Ponce-Alvarez, A., Idesis, S., … Deco, G. · Human Brain Mapping, 2026
- Identifier
- doi:10.1002/hbm.70596 · PMC13318930
- License
- CC BY-NC 4.0: cited only, figures not reproduced.
- Funding
- Alexander von Humboldt Foundation (Feodor Lynen Scholarship); National Institutes of Health (K99/R00-AG065457)
- Conflicts
- L. Pasquini: scientific advisor for AWEAR Technologies (per the paper). R. L. Carhart-Harris: advisor to Otsuka, MindState and Entheos Labs (per the paper).
- Corrections
- None known.
- Reading
- Full read reported by AIThe drafting AI recorded a full read on 10 October 2026. No human signature is recorded.Astra checked only part of the text on 11 October 2026.
Bhagavan 2026
Sustained Effects of Low-to-Moderate Doses of Psilocybin on Brain Connectivity
Bhagavan, C., Dandash, O., Carter, O., Bryson, A., & Kanaan, R. A. · medRxiv (preprint), 2026
- Identifier
- doi:10.64898/2026.04.17.26351147
- License
- Unknown: cited only, figures not reproduced.
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Abstract onlyRecorded before the two-model checking and signing process.
Madsen 2024
CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity
Madsen, M. K., Petersen, A. S., Stenbaek, D. S., Sørensen, I. M., Schiønning, H., Fjeld, T., … Knudsen, G. M. · Headache, 2024
- Identifier
- doi:10.1111/head.14656
- License
- Unknown: cited only, figures not reproduced.
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Abstract onlyRecorded before the two-model checking and signing process.
Brendstrup-Brix 2026
Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache
Brendstrup-Brix, K., Ozenne, B., Fisher, P. M., Stenbæk, D. S., Petersen, A. S., Armand, S., … Madsen, M. K. · Journal of Psychopharmacology, 2026
- Identifier
- doi:10.1177/02698811261449380
- License
- Unknown: cited only, figures not reproduced.
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Read in partRecorded before the two-model checking and signing process.
Harding 2025
Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises
Harding, R., Singer, N., Wall, M. B., Hendler, T., Erritzoe, D., Nutt, D., … Roseman, L. · Molecular Psychiatry, 2025
- Identifier
- doi:10.1038/s41380-025-03035-8 · PMC12185350
- License
- CC BY 4.0: figures may be rebuilt with attribution.
- Funding
- Alexander Mosley Charitable Trust; Founding partners of Imperial College London's Centre for Psychedelic Research
- Conflicts
- R. Carhart-Harris: consulting fees from Mindstate and Entheos Labs (per the paper). D. Erritzoe and D. Nutt: fees from psychedelic and pharmaceutical companies, and Nutt holds stock (per the paper). M. B. Wall: employed by Invicro, a contract research organisation (per the paper).
- Corrections
- A published correction changed the abstract to ‘decreased activation in the ventromedial prefrontal cortex’. This record follows the correction.
- Reading
- Full read reported by AIThe drafting AI recorded a full read on 10 October 2026. No human signature is recorded.
Farré-Colomés 2026
Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies
Farré-Colomés, À., Rublinetska, O., & Soto-Angona, Ó. · Discover Mental Health, 2026
- Identifier
- doi:10.1007/s44192-026-00384-w · PMC13003063
- License
- CC BY 4.0: figures may be rebuilt with attribution.
- Funding
- No specific grant (per the paper)
- Conflicts
- Declared none.
- Corrections
- None known.
- Reading
- Full read reported by AIThe drafting AI recorded a full read on 10 October 2026. No human signature is recorded.Astra checked only part of the text on 11 October 2026.
Sabbah 2026
Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal
Sabbah, S. G., Li, S., Wong, S., Le, G. H., Badulescu, S., Hawco, C., … McIntyre, R. S. · Journal of Affective Disorders, 2026
- Identifier
- doi:10.1016/j.jad.2025.120335
- License
- Unknown: cited only, figures not reproduced.
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Abstract onlyRecorded before the two-model checking and signing process.
Kramer 2026
Psychedelics produce enduring behavioral effects and functional plasticity through mechanisms independent of structural plasticity
Kramer, H. M., Hibicke, M., Middleton, J., Jaster, A. M., Kristensen, J. L., & Nichols, C. D. · Neuropsychopharmacology, 2026
- Identifier
- doi:10.1038/s41386-025-02272-3
- License
- Unknown: cited only, figures not reproduced.
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Abstract onlyRecorded before the two-model checking and signing process.
Gudmundsen 2026
Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networks
Gudmundsen, F., Czurylo, J., Rijsketic, D. R., Vo, C. T., Fortunato, J., Jessen, N. S., … Palner, M. · Nature Communications, 2026
- Identifier
- doi:10.1038/s41467-026-75890-0 · PMC13529806
- License
- CC BY-NC-ND 4.0: cited only, figures not reproduced.
- Funding
- Independent Research Fund Denmark; Novo Nordisk Foundation; Lundbeck Foundation; Neuroscience Academy Denmark; National Institutes of Health
- Conflicts
- M. Palner: owns shares in Compass Pathways and ATAI and consults for BrandarisTx (per the paper). B. D. Heifets: co-founder of Ocellaris and paid consultant or advisor to several companies (per the paper).
- Corrections
- None known.
- Reading
- Full read reported by AIThe drafting AI recorded a full read on 10 October 2026. No human signature is recorded.
Keenan 2026
Effects of a single dose of psilocybin on diet-induced weight loss in obese mice
Keenan, R. J., Haque, R. T., Jin, X., Mustafa, T., Homman-Ludiye, J., Elysee, K., … Cowley, M. A. · Translational Psychiatry, 2026
- Identifier
- doi:10.1038/s41398-026-03995-7 · PMC13187204
- License
- CC BY-NC-ND 4.0: cited only, figures not reproduced.
- Funding
- National Health and Medical Research Council (Australia)
- Conflicts
- C. J. Foldi: scientific advisory board of Octarine Bio (per the paper).
- Corrections
- None known.
- Reading
- Full read reported by AIThe drafting AI recorded a full read on 10 October 2026. No human signature is recorded.
Sahoo 2026
Sex-dependent developmental changes in behavior, brain structure, functional connectivity, and sensory perception following exposure to psilocybin during adolescence
Sahoo, I., Masadi, S., Maheswari, A., Utama, R., Abeer, M. I., Soltanpour, S., … Ferris, C. F. · Neuropsychopharmacology, 2026
- Identifier
- doi:10.1038/s41386-026-02356-8 · PMC13212770
- License
- CC BY 4.0: figures may be rebuilt with attribution.
- Funding
- Ekam Imaging
- Conflicts
- C. F. Ferris and P. P. Kulkarni: partnership interest in Ekam Imaging, the funder (per the paper).
- Corrections
- None known.
- Reading
- Full read reported by AIThe drafting AI recorded a full read on 10 October 2026. No human signature is recorded.Astra checked only part of the text on 11 October 2026.
García-Cabrerizo 2025
Psilocybin as a fast-acting and long-lasting antidepressant for adolescence: Proposing NeuroD1 as a biomarker of its long-term plasticity
García-Cabrerizo, R., Beruete-Fresnillo, I., Bergas-Cladera, P., & García-Fuster, M. J. · Biomedicine & Pharmacotherapy, 2025
- Identifier
- doi:10.1016/j.biopha.2025.118720
- License
- Unknown: cited only, figures not reproduced.
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Read in partRecorded before the two-model checking and signing process.
Raison 2023
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., …, … Griffiths, R. R. · JAMA, 2023
- Identifier
- doi:10.1001/jama.2023.14530
- License
- Unknown: cited only, figures not reproduced.
- Conflicts
- Not recorded here; check the paper’s statement.
- Corrections
- None known.
- Reading
- Abstract onlyRecorded before the two-model checking and signing process.
Erritzoe 2024
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
Erritzoe, D., Barba, T., Greenway, K. T., Murphy, R., Martell, J., Giribaldi, B., … Carhart-Harris, R. · eClinicalMedicine, 2024
- Identifier
- doi:10.1016/j.eclinm.2024.102799 · PMC11701471
- License
- CC BY-NC 4.0: cited only, figures not reproduced.
- Funding
- The Alexander Mosley Charitable Trust; The founding partners of Imperial College London's Centre for Psychedelic Research
- Conflicts
- Several authors report advisory, consulting or stock interests in psychedelic companies (among them Mindstate Design Lab, COMPASS Pathways, Cybin and Beckley Psytech); COMPASS Pathways supplied the study drug and, by contract with Imperial College (the sponsor), had access to safety data.
- Corrections
- None known.
- Reading
- Full read reported by AIThe drafting AI recorded a full read on 11 October 2026. No human signature is recorded.
Living log
This page is versioned. Each revision is listed here.
Wording
Three draft predictions added. They are not yet committed tests.
Conclusion changed
An automated review (an AI model run outside this repository) of the map's claims against the papers found that c-mouse-mechanism attributed activity dependence to dendritic-spine remodeling. Jiang 2026 traced the inputs to frontal cortex neurons; its silencing result concerns those inputs, not spines. The claim, its basis and its would-change line now say what Jiang 2026's abstract reports, and so do the two passages in the page text that repeated it. Its tier is unchanged. The relation r-measure-split, whose statement describes spine persistence, now links the spine-persistence claim (c-mouse-spines-persist) instead of c-mouse-mechanism.
Wording
Added the map's event history: 86 dated events recording when each claim and relation was added, restated or given new sources, reconstructed from git (31 from the Oryx repository, where the map began, and 55 from this one). No claim, tier or conclusion changed.
Conclusion changed
Before version 2.2 was published, an independent automated check of its claims against the papers, run outside this repository, and two automated stress tests found errors and overstatement. Neither is peer review. The posed reading is now an explicit, untested question: the earlier text said population, measure and species line up with much of the disagreement, which these sources do not establish, and said symptom effects in patients were not established beyond about three weeks, which the imaging horizon does not show. Added Raison 2023 (a placebo-controlled single-dose trial, day 43) and Erritzoe 2024 (the escitalopram trial's observational six-month follow-up) as clinical context in a new claim; the shared-program count rose to six papers on three cohorts. Corrected: Brendstrup-Brix had 8 of 11 patients with complete follow-up and reuses Madsen's trial; Harding's result is a greater pre/post decrease than escitalopram, in vmPFC and right angular gyrus; García-Cabrerizo's NeuroD1 result is at 1 mg/kg only, measured a day after the behaviour; Siegel's persistence is an exploratory, uncorrected analysis in six people pooled over three weeks; nulls are stated as nondetections; the Kramer structural result is not split by drug; Sabbah's 5+ week timing is left unresolved; and the Keenan and Shao comparison notes their different regions. Several sources remain abstract-only or partly read, and each claim says so.
v2.2Sources added
Added twelve studies from 2024 to 2026 that measure the brain a week or more after dosing, from the first screening of the 2026-09-28 scan (161 candidates from those years) and an OpenAlex and Europe PMC search (174 more); every decision and reason is in the dated screening file beside the snapshot. New claims: healthy volunteers at one and four weeks (Pasquini, Bhagavan), cluster headache patients at one week (Madsen, Brendstrup-Brix), depression patients' task fMRI at three weeks (Harding), two systematic reviews on thin follow-up (Farré-Colomés, Sabbah), rats months after one dose (Kramer), rats and mice at one week to a month (Gudmundsen, Keenan) and repeated adolescent dosing (Sahoo, García-Cabrerizo). Each is tiered preliminary. One existing claim changed because of the new sources: the shared-program count rose from three human studies to five. No other existing claim, tier or conclusion changed; the posed reading has not been re-tested against these studies.
v2.1Sources added
Added Johansen et al. 2026 (Translational Psychiatry, CC BY 4.0) as contrary evidence: in 15 healthy adults, no significant overall increase in synaptic density one week after a dose, with an exploratory setting subgroup pointing the other way. Softened the summary: population, measure and species line up with much of the disagreement, but dose, setting and timing are competing explanations. The posed reading is scoped to the nine studies it was stress-tested against; it has not been re-tested with the tenth. The AI passes are now described as automated stress tests.
Wording
Corrections and presentation. The outcomes chart now shows each outcome as a mean difference with its 95% confidence interval in the measure's own units. For cognitive flexibility, Lyons et al. give Cohen's d = 0.5 in the Results text and 0.6 in the Fig. 4D legend for the same contrast. The legend adds “outlier corrected”, and the paper does not say which d belongs to which analysis; no correction notice exists, so the chart shows both values and says why. Siegel's follow-up is now stated from the paper (three weeks post-dose; back at baseline at a 6 to 12 month revisit, n = 4) and its license checked (CC BY 4.0). Review status clarified: the adversarial passes were run by AI agents against the stated claims, not full texts, and independent expert review has not happened yet. Earlier notes said it was pending before publication; it was not a gate that was applied before this page went live. No claim, tier or conclusion changed.
Wording
Moved to PsychDoc.AI, now this synthesis's canonical home; citation permalinks point to psychdoc.ai. Attribution changed from Oryx to PsychDoc and punctuation edited to house style; no claim, tier or conclusion changed.
v2.0Conclusion changed
The first scheduled scan (2026-09-28) found four papers the hand-picked set missed, each linked to three or four of the original five: Carhart-Harris 2021 and Goodwin 2022 (NEJM trials), Shao 2021 (mouse spines) and Siegel 2024 (healthy-volunteer precision imaging). Siegel narrowed the posed reading's population axis: lasting functional change in healthy volunteers is narrow, not absent. The independence rule was tightened so a single shared mid-list co-author ties two programs instead of merging them. The posed reading was re-verified by two independent adversarial reviews; their required edits (dose, support and timing confounds; measure overlapping species; co-authorship across every human finding) are applied.
Wording
Added would-change-if lines to the three headline claims and the corpus spec (field query, seeds, screening criteria) that drives the scheduled scan. No conclusion changed.
v1.0Revision
Initial synthesis across 5 sources. Novel population×measure×species reading double-checked inline (confound + completeness passes); independent expert review pending before publication.
Corpus scan of 9 November 2026: 1,670 candidates around 24 seed papers, 294 linked to two or more seeds. Screening has decided 276 of 294 linked works: 103 included, 18 still pending. 121 included or pending works are not yet sources. Scheduled scan (GitHub Actions corpus-refresh, run 42723636091). Generated: assisted. Created 19 July 2026, updated 9 November 2026.
Cite
Cite this synthesis
PsychDoc.AI. (2026). Does one dose of psilocybin rewire the brain? (updated 2026-11-09). https://psychdoc.ai/evidence/psilocybin-rewiring
BibTeX
@misc{psychdoc_psilocybin_rewiring_2026,
author = {PsychDoc.AI},
title = {Does one dose of psilocybin rewire the brain?},
year = {2026},
howpublished = {\url{https://psychdoc.ai/evidence/psilocybin-rewiring}},
note = {synthesis object; published 2026-07-19, updated 2026-11-09}
}Cite the sources
- Lyons, T., Spriggs, M., …, & Carhart-Harris, R. L. (2026). Human brain changes after first psilocybin use. Nature Communications. https://doi.org/10.1038/s41467-026-71962-3
- Daws, R. E., Timmermann, C., …, & Carhart-Harris, R. (2022). Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine. https://doi.org/10.1038/s41591-022-01744-z
- Jiang, Q., Shao, L.-X., …, & Kwan, A. C. (2026). Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks. Cell. https://doi.org/10.1016/j.cell.2025.11.009
- Nardou, R., Sawyer, E., …, & Dölen, G. (2023). Psychedelics reopen the social reward learning critical period. Nature. https://doi.org/10.1038/s41586-023-06204-3
- Novelli, L., Stoliker, D., …, & Razi, A. (2025). PsiConnect: A Multimodal Neuroimaging Study of Psilocybin-Induced Changes in Brain and Behaviour. bioRxiv (preprint). https://doi.org/10.1101/2025.04.11.643415
- Carhart-Harris, R., Giribaldi, B., …, & Nutt, D. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2032994
- Goodwin, G. M., Aaronson, S. T., …, Carhart-Harris, R. L., …, Dunlop, B. W., … Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2206443
- Shao, L.-X., Liao, C., …, & Kwan, A. C. (2021). Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. https://doi.org/10.1016/j.neuron.2021.06.008
- Siegel, J. S., Subramanian, S., …, Raison, C. L., …, Carhart-Harris, R. L., … Dosenbach, N. U. F. (2024). Psilocybin desynchronizes the human brain. Nature. https://doi.org/10.1038/s41586-024-07624-5
- Johansen, A., Plavén-Sigray, P., Madsen, M. K., …, & Knudsen, G. M. (2026). Psilocybin’s effect on human brain synaptic plasticity. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04285-y
- Pasquini, L., Vohryzek, J., Escrichs, A., Perl, Y. S., Ponce-Alvarez, A., Idesis, S., … Deco, G. (2026). Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits. Human Brain Mapping. https://doi.org/10.1002/hbm.70596
- Bhagavan, C., Dandash, O., Carter, O., Bryson, A., & Kanaan, R. A. (2026). Sustained Effects of Low-to-Moderate Doses of Psilocybin on Brain Connectivity. medRxiv (preprint). https://doi.org/10.64898/2026.04.17.26351147
- Madsen, M. K., Petersen, A. S., Stenbaek, D. S., Sørensen, I. M., Schiønning, H., Fjeld, T., … Knudsen, G. M. (2024). CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity. Headache. https://doi.org/10.1111/head.14656
- Brendstrup-Brix, K., Ozenne, B., Fisher, P. M., Stenbæk, D. S., Petersen, A. S., Armand, S., … Madsen, M. K. (2026). Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache. Journal of Psychopharmacology. https://doi.org/10.1177/02698811261449380
- Harding, R., Singer, N., Wall, M. B., Hendler, T., Erritzoe, D., Nutt, D., … Roseman, L. (2025). Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises. Molecular Psychiatry. https://doi.org/10.1038/s41380-025-03035-8
- Farré-Colomés, À., Rublinetska, O., & Soto-Angona, Ó. (2026). Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies. Discover Mental Health. https://doi.org/10.1007/s44192-026-00384-w
- Sabbah, S. G., Li, S., Wong, S., Le, G. H., Badulescu, S., Hawco, C., … McIntyre, R. S. (2026). Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.120335
- Kramer, H. M., Hibicke, M., Middleton, J., Jaster, A. M., Kristensen, J. L., & Nichols, C. D. (2026). Psychedelics produce enduring behavioral effects and functional plasticity through mechanisms independent of structural plasticity. Neuropsychopharmacology. https://doi.org/10.1038/s41386-025-02272-3
- Gudmundsen, F., Czurylo, J., Rijsketic, D. R., Vo, C. T., Fortunato, J., Jessen, N. S., … Palner, M. (2026). Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networks. Nature Communications. https://doi.org/10.1038/s41467-026-75890-0
- Keenan, R. J., Haque, R. T., Jin, X., Mustafa, T., Homman-Ludiye, J., Elysee, K., … Cowley, M. A. (2026). Effects of a single dose of psilocybin on diet-induced weight loss in obese mice. Translational Psychiatry. https://doi.org/10.1038/s41398-026-03995-7
- Sahoo, I., Masadi, S., Maheswari, A., Utama, R., Abeer, M. I., Soltanpour, S., … Ferris, C. F. (2026). Sex-dependent developmental changes in behavior, brain structure, functional connectivity, and sensory perception following exposure to psilocybin during adolescence. Neuropsychopharmacology. https://doi.org/10.1038/s41386-026-02356-8
- García-Cabrerizo, R., Beruete-Fresnillo, I., Bergas-Cladera, P., & García-Fuster, M. J. (2025). Psilocybin as a fast-acting and long-lasting antidepressant for adolescence: Proposing NeuroD1 as a biomarker of its long-term plasticity. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2025.118720
- Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., …, … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2023.14530
- Erritzoe, D., Barba, T., Greenway, K. T., Murphy, R., Martell, J., Giribaldi, B., … Carhart-Harris, R. (2024). Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. eClinicalMedicine. https://doi.org/10.1016/j.eclinm.2024.102799
